<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5760508</article-id><article-id pub-id-type="doi">10.3389/fimmu.2017.01932</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>MicroRNA-155&#8212;at the Critical Interface of Innate and Adaptive Immunity in Arthritis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Alivernini</surname><given-names>Stefano</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/503006"/></contrib><contrib contrib-type="author"><name><surname>Gremese</surname><given-names>Elisa</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>McSharry</surname><given-names>Charles</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tolusso</surname><given-names>Barbara</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ferraccioli</surname><given-names>Gianfranco</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>McInnes</surname><given-names>Iain B.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kurowska-Stolarska</surname><given-names>Mariola</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1">*</xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/360120"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Institute of Rheumatology &#8211; Fondazione Policlinico Universitario A. Gemelli, Catholic University of the Sacred Heart</institution>, <addr-line>Rome</addr-line>, <country>Italy</country></aff><aff id="aff2"><sup>2</sup><institution>Institute of Infection, Immunity and Inflammation, University of Glasgow</institution>, <addr-line>Glasgow</addr-line>, <country>United Kingdom</country></aff><aff id="aff3"><sup>3</sup><institution>Rheumatoid Arthritis Pathogenesis Centre of Excellence (RACE)</institution>, <addr-line>Glasgow</addr-line>, <country>United Kingdom</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Massimo Gadina, National Institute of Arthritis and Musculoskeletal and Skin Diseases, United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Michael Bonelli, Medical University of Vienna, Austria; Devendra K. Agrawal, Creighton University, United States</p></fn><corresp content-type="corresp" id="cor1">*Correspondence: Mariola Kurowska-Stolarska, <email>mariola.kurowska-stolarska@glasgow.ac.uk</email></corresp><fn fn-type="other" id="fn001"><p>Specialty section: This article was submitted to Inflammation, a section of the journal Frontiers in Immunology</p></fn></author-notes><pub-date pub-type="epub"><day>05</day><month>1</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>8</volume><elocation-id>1932</elocation-id><history><date date-type="received"><day>31</day><month>8</month><year>2017</year></date><date date-type="accepted"><day>15</day><month>12</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#169; 2018 Alivernini, Gremese, McSharry, Tolusso, Ferraccioli, McInnes and Kurowska-Stolarska.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Alivernini, Gremese, McSharry, Tolusso, Ferraccioli, McInnes and Kurowska-Stolarska</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>MicroRNAs (miRNAs) are small non-coding RNAs that fine-tune the cell response to a changing environment by modulating the cell transcriptome. miR-155 is a multifunctional miRNA enriched in cells of the immune system and is indispensable for the immune response. However, when deregulated, miR-155 contributes to the development of chronic inflammation, autoimmunity, cancer, and fibrosis. Herein, we review the evidence for the pathogenic role of miR-155 in driving aberrant activation of the immune system in rheumatoid arthritis, and its potential as a disease biomarker and therapeutic target.</p></abstract><kwd-group><kwd>microRNA-155</kwd><kwd>inflammation</kwd><kwd>antibody production</kwd><kwd>arthritis rheumatoid</kwd><kwd>autoimmunity</kwd></kwd-group><funding-group><award-group><funding-source id="cn01">Arthritis Research UK<named-content content-type="fundref-id">10.13039/501100000341</named-content></funding-source><award-id rid="cn01">RACE20298</award-id></award-group></funding-group><counts><fig-count count="5"/><table-count count="0"/><equation-count count="0"/><ref-count count="165"/><page-count count="16"/><word-count count="12707"/></counts></article-meta></front><body><sec sec-type="introduction" id="S1"><title>Introduction</title><p>Epigenetic modification represents an important mechanism of regulating gene expression that enables cells to respond appropriately to a changing environment. The mechanisms of epigenetic modification include, e.g., acetylation of histones, methylation of gene promoters, and silencing of mRNA transcripts by microRNAs (miRNA) (<xref rid="B1" ref-type="bibr">1</xref>). miRNAs are a family of short, non-coding RNAs, acting at the posttranscriptional level (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>), that fine-tune mRNA transcription (<xref rid="B4" ref-type="bibr">4</xref>). More than 2,000 miRNAs have been identified in humans, and computational predictions show that these regulate the expression of approximately 60% of all human protein-coding genes (<xref rid="B5" ref-type="bibr">5</xref>). miRNAs are pleotropic; a single miRNA can regulate a cellular response by targeting multiple components of a biological pathway (<xref rid="B2" ref-type="bibr">2</xref>). More than 100 different miRNAs are expressed by cells of the immune system together influencing the pathways that control the development and function of cells of innate and adaptive immune responses (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>). Identifying disease-specific miRNAs improved the understanding of molecular pathways involved in diseases, and provided an evidence-base for new therapeutic strategies, e.g., in cancer (<xref rid="B8" ref-type="bibr">8</xref>) and tendinopathy (<xref rid="B9" ref-type="bibr">9</xref>).</p><p>Rheumatoid arthritis (RA) is an autoimmune disease that affects approximately 1% of the global population and leads to progressive loss of joint function (<xref rid="B10" ref-type="bibr">10</xref>). Currently, more than half of RA patients do not achieve sustained drug-induced disease remission (<xref rid="B11" ref-type="bibr">11</xref>), which constitutes an important clinical unmet need. A better understanding of the disease process is required to improve the treatment options for patients resistant to current therapeutics and to provide an evidence base for personalized medicine.</p><p>A decade of research has shown that aberrant expression of miRNAs underlies the immune response and stromal cell activation in RA (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B12" ref-type="bibr">12</xref>). miR-155 is a master-regulator of the immune response and the aim of the present review is to discuss its role in the immuno-pathogenesis of RA and its potential as a disease activity biomarker and therapeutic target.</p></sec><sec id="S2"><title>miRNA Biogenesis and Mechanism of Action</title><p>MicroRNAs are ~23&#8201;nt small non-coding RNAs that regulate mRNA expression at the posttranscriptional level by directing mRNA degradation or translational repression. They fine-tune expression of their target genes (by approximately 1.2-fold to fourfold) and correspondingly affect biological pathway function (<xref rid="B2" ref-type="bibr">2</xref>). miRNAs bind complementary seed-region sequences in the 3&#8242; untranslated regions (UTRs) of specific target mRNAs leading to the repression of protein production. Each miRNA has the potential to repress many target mRNAs, often in the same molecular pathway, highlighting the sophistication of this epigenetic regulation.</p><p>MicroRNAs emerge from long primary transcripts (pri-miRNAs) transcribed from independent miRNA coding genes or from introns of protein-coding mRNAs (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>). After transcription, pri-miRNAs are capped, poly-adenylated, and then cleaved into ~70&#8201;nt hairpin structures (pre-miRNAs) by a nuclear microprocessor complex composed of RNase III-type endonuclease Drosha and the DiGeorge critical region 8 protein. DGCR8 is essential for Drosha activity and is capable of binding single-stranded fragments of the pri-miRNA that are required for proper processing. Pre-miRNAs are then exported from the nucleus to the cytoplasm through Exportin-5 in a GTP-dependent mechanism. In the cytoplasm, pre-miRNAs are then cleaved by Dicer; a RNase III-type enzyme that acts with its cofactor TAR RNA-binding protein 2 resulting in RNA duplexes of ~22&#8211;23&#8201;nt in length. Subsequently, an argonaute (Ago) protein and a 182-kDa glycine&#8211;tryptophan repeat-containing protein bind to these RNA duplexes forming the core of a multi-subunit complex called the miRNA-mediated silencing complex (miRISC). Once assembled into the miRISC, through base-pairing interactions between nucleotides 2 and 8 of the miRNA (the seed region) and complementary nucleotides predominantly in the 3&#8242;-UTR of mRNAs, they act as repressor of mRNA translation (<xref rid="B15" ref-type="bibr">15</xref>&#8211;<xref rid="B18" ref-type="bibr">18</xref>).</p><p>The miR-155 gene was initially described as the B-cell integration cluster gene (<italic>bic</italic>) in chickens, which induced leucocytosis when activated by a viral promoter insertion that increased <italic>bic</italic> transcription (<xref rid="B19" ref-type="bibr">19</xref>). Following this finding, a homologous gene to <italic>bic</italic> was identified in humans and mice (<xref rid="B20" ref-type="bibr">20</xref>). Human and murine <italic>bic</italic> cDNA have &gt;70% identity (<xref rid="B20" ref-type="bibr">20</xref>). <italic>Bic</italic> is strongly expressed in the thymus and spleen, and can be detected in other tissues, including liver, lung, and kidney (<xref rid="B20" ref-type="bibr">20</xref>&#8211;<xref rid="B22" ref-type="bibr">22</xref>). At the cellular level, analysis of small RNA clone libraries by Landgraf and colleagues demonstrated that miR-155 is expressed in hematopoietic stem-progenitor cells and mature hematopoietic cells, including monocytes, granulocytes, B-cells, and T-cells (<xref rid="B23" ref-type="bibr">23</xref>). Subsequent experiments showed that miR-155 plays an essential role in controlling both myelopoiesis and erythropoiesis from CD34<sup>+</sup> hematopoietic stem-progenitor cells (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>).</p><p>The miRNA duplex contains two strands identified with either the suffix -5p (from the 5&#8242; arm of pre-miR; i.e., miR-155-5p) or -3p (from the 3&#8242; arm of pre-miR; i.e., miR-155-3p) (<xref rid="B26" ref-type="bibr">26</xref>). One of the strands of the duplex is normally discarded (the passenger strand; annotated *) while the retained strand guides eventual mRNA target selection (the guide strand). Thermodynamic properties of the duplex appear to determine strand selection; the strand with the weakest binding at the 5&#8242;-end of the duplex is more likely to become the guide strand. Other key characteristics of miRNA guide strands are a U-bias at the 5&#8242;-end and an excess of purines (A/G rich), whereas the passenger strands have a C-bias at the 5&#8242;-end and an excess of pyrimidines (U/C rich) (<xref rid="B27" ref-type="bibr">27</xref>). However, the preferred guide strand can be changed by a single point mutation in the duplex (<xref rid="B28" ref-type="bibr">28</xref>), posttranscriptional modification of the duplex (<xref rid="B29" ref-type="bibr">29</xref>), and the type of proteins associated with Ago2 in the RISC complex (e.g., trans-activation response RNA-binding protein versus protein activator of dsRNA-dependent protein kinase) (<xref rid="B30" ref-type="bibr">30</xref>). Thus, there is increasing evidence demonstrating that both arms of the pre-miRNA hairpin can give rise to guide miRNAs (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>) that are biologically functional. In general, miR-155-3p is considered to be the passenger strand (*), and its expression levels are typically 20-fold to 200-fold lower than miR-155-5p. However, despite this difference in expression level, miR-155-3p (*) can be functional, e.g., following TLR7 ligand stimulation of plasmocytoid dendritic cells (pDCs), miR-155-3p is rapidly upregulated while miR-155-5p is induced at a later stage (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>). miR-155-3p acts at an early stage by targeting interleukin-1 receptor-associated kinase 3 (IRAK3/IRAKM) mRNA which is a negative regulator of toll-like receptor signaling, facilitating TLR7-induced IFN&#945;/&#946; production, and the later induction of miR-155-5p (miR-155) terminates this production by targeting TGF-&#946; activated kinase 1/MAP3K7 binding protein 2 (TAB 2) mRNA, a key signaling molecule of TLRs (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>). Thus, both strands of the miR-155 duplex are required for an efficiently co-ordinated pDCs response. Most studies have investigated the biology of the miR-155-5p strand and further studies are recommended to investigate the evidence for a role of miR-155*(3p) in the regulation of the immune system and disease.</p></sec><sec id="S3"><title>The Regulation of miR-155 Expression</title><p>miR-155 expression is rapidly increased in response to infection or injury. Inducing factors include pathogen-associated molecular patterns and damage-associated molecular patterns (PAMPs/DAMPs (<xref rid="B35" ref-type="bibr">35</xref>)), alarmins (e.g., IL-1&#945;) (<xref rid="B36" ref-type="bibr">36</xref>), and inflammatory stimuli, e.g., TNF, IL-1&#946;, interferons (<xref rid="B35" ref-type="bibr">35</xref>), and hypoxia (<xref rid="B37" ref-type="bibr">37</xref>). In contrast, the expression of miR-155 is decreased by anti-inflammatory cytokines, resolvins, glucocorticoids, and posttranscriptional negative regulators, e.g., tristetraprolin; and this decreased expression of miR-155 is an important part of the negative-feedback mechanism terminating immune responses. For example, IL-10 decreases miR-155 expression by inhibiting the transcription factor Ets2. Thus, LPS-induced miR-155 expression is attenuated in Ets2-deficient mice (<xref rid="B38" ref-type="bibr">38</xref>). Regulatory cytokines, e.g., TGF&#946; can induce or inhibit miR-155 expression depending on the cell type and tissue environment (<xref rid="B39" ref-type="bibr">39</xref>&#8211;<xref rid="B41" ref-type="bibr">41</xref>). Resolvins are lipid mediators produced, e.g., by tissue macrophages, upon activation of Tyrosine-protein kinase Mer (MerTK) by apoptotic inflammatory cells (<xref rid="B42" ref-type="bibr">42</xref>) and have broad anti-inflammatory effects. Resolvin D1 reduces inflammation in experimental corneal immunopathology by inhibiting miR-155 expression (<xref rid="B43" ref-type="bibr">43</xref>). Natural and synthetic glucocorticoids are highly effective at terminating acute inflammation, mediated in part by inhibition of miR-155 expression in a glucocorticoids receptor- and NF-&#954;B-dependent manner (<xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B45" ref-type="bibr">45</xref>). Inflammation can be controlled by the short half-life of mRNA of pro-inflammatory mediators (e.g., TNF, GM-CSF, IL-8, and CCL2). The rapid elimination of these mRNAs is mediated by miRNAs; or by specific proteins, e.g., tristetraprolin (TTP/ZFP36) that recognizes adenine&#8211;uridine rich elements (AREs) in mRNA and orchestrate its degradation. TTP inhibits miR-155, albeit by an unusual mechanism. Cells that overexpress TTP show high levels of miR-1 that putatively prevents the processing of miR-155 precursor to the mature form (<xref rid="B46" ref-type="bibr">46</xref>). In addition, the functions of mature miR-155 are counterbalanced by other miRs and the best example is miR-146. This, induced by the same stimuli as miR-155, targets TRAF6 and IRAK1 of the TLR/IL-1R signaling pathway and the timing of this provides feedback inhibition of the inflammatory response driven by miR-155 (<xref rid="B47" ref-type="bibr">47</xref>). This is evident in miR-146-deficient mice that develop inflammatory syndrome, autoimmunity, and cancer. miR-146-deficient cells show an increased expression of miR-155 and their pro-inflammatory phenotype could be normalized by deletion of miR-155 (<xref rid="B48" ref-type="bibr">48</xref>), thus miR-155 and miR-146 can cross-regulate inflammatory responses.</p><p>The miR-155 gene contains binding sites for multiple transcription factors including sites localized downstream and upstream of exon 1, e.g., 2 NF-&#954;B binding sites (&#8722;1,697 and &#8722;1,150&#8201;bp from the transcription initiation site, respectively), SMAD4 (&#8722;600&#8201;bp), interferon-sensitive response element ISRE (&#8722;311&#8201;bp), interferon regulatory factors IRF (&#8722;200&#8201;bp), and AP-1 (&#8722;40&#8201;bp). There are also two Ets binding sites within the transcription start site, two Foxp3 binding sites in intron 2, and three hypoxia-inducible factor-1 alpha binding sites in the promoter region (<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B49" ref-type="bibr">49</xref>). This reflects the role of miR-155 in co-ordination of the cell response to changes in the tissue environment (<xref rid="B49" ref-type="bibr">49</xref>).</p></sec><sec id="S4"><title>The Functions of miR-155 in Innate Immune Cells and Its Deregulation in RA</title><sec id="S4-1"><title>miR-155 Regulates Polarization of Macrophages</title><p>Macrophages can be polarized into different phenotypes in response to changes in tissue environments (<xref rid="B50" ref-type="bibr">50</xref>). For example, during bacterial infection, TLRL- or T-helper 1 (Th1)/ILC1-derived IFN&#947; polarizes the pro-inflammatory macrophage phenotype that drives the protective immune response. However, if uncontrolled, this leads to chronic inflammation (<xref rid="B50" ref-type="bibr">50</xref>). Homeostasis can be restored by IL-10 and TGF&#946; derived from regulatory T-cells and by glucocorticoids, that induce macrophage phenotypes that mediate resolution of the immune response and facilitate tissue repair. IL-4/13 derived from Th2/ILC2 induces alternative macrophage phenotypes that are key in eliminating the parasites (<xref rid="B51" ref-type="bibr">51</xref>). However, they are also involved in mediating tissue repair by producing collagen components (proline), TGF&#946;, and CCL18. These changes in macrophage phenotypes are co-ordinated by miRNA networks, including miR-155 (<xref rid="B52" ref-type="bibr">52</xref>).</p><p>miR-155 is induced in monocyte/macrophages upon TLR/IFN&#947; stimulation and drives their inflammatory response by epigenetic regulation of mRNA targets that are inhibitors of innate cell activation, e.g.,
<list list-type="simple"><list-item><label>(i)</label><p>phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1 (SHIP-1); an inhibitor of TLR/PI3/Akt kinase pathways.</p></list-item><list-item><label>(ii)</label><p>SOCS-1; a type 1 cytokine receptor/STAT pathway inhibitor.</p></list-item><list-item><label>(iii)</label><p>Bcl6, an inhibitor of NF-&#954;B (<xref rid="B53" ref-type="bibr">53</xref>&#8211;<xref rid="B56" ref-type="bibr">56</xref>).</p></list-item></list></p><p>Bone marrow-derived murine macrophages deficient for miR-155 express decreased levels of pro-inflammatory cytokines following LPS stimulation (<xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B57" ref-type="bibr">57</xref>), as do miR-155-deficient murine RAW264.7 macrophages (<xref rid="B58" ref-type="bibr">58</xref>) and human macrophages gene-silenced for miR-155 (<xref rid="B57" ref-type="bibr">57</xref>); each associated with commensurate upregulation of SHIP-1.</p><p>In contrast to pro-inflammatory activation of macrophages, miR-155 inhibits the polarization of anti-inflammatory and repair macrophage phenotypes. miR-155 targets translation of multiple molecules in the IL-13/IL-4 pathway, including IL-13R&#945;, CEBP/&#946; (<xref rid="B59" ref-type="bibr">59</xref>), and Mafb (<xref rid="B60" ref-type="bibr">60</xref>) and thus prevents development of the STAT6-driven anti-inflammatory and helminth-expulsive macrophage phenotype (<xref rid="B61" ref-type="bibr">61</xref>). Furthermore, miR-155 regulates the TGF-&#946; signaling pathway, which is crucial for wound healing and homeostatic remodeling (<xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B63" ref-type="bibr">63</xref>). Louafi and colleagues found that miR-155 represses the TGF&#946; signaling molecule Smad2 in macrophages, preventing TGF&#946;-induced expression of IL-4R&#945;, amplification of TGF&#946;1/2 production, and the development of repair macrophages (<xref rid="B63" ref-type="bibr">63</xref>). We recently extended these findings by showing that miR-155 negatively regulates remodeling pathways in alveolar macrophages by targeting the transcription factor LXR&#945;. miR-155-deficient mice had exacerbated bleomycin-induced lung fibrosis compared to WT mice given bleomycin, and their alveolar macrophages showed an increased expression of <italic>Arginase 2</italic>, which is key for collagen production (<xref rid="B36" ref-type="bibr">36</xref>). Thus, miR-155 is a master-switch that determines the relative dynamics of TLR-induced inflammatory and IL-13/IL-4 or TGF&#946;-induced anti-inflammatory/repair phenotypes in macrophages (Figure <xref ref-type="fig" rid="F1">1</xref>). Inhibition of miR-155, e.g., by glucocorticoids or by regulatory T-cell-derived mediators (e.g., IL-10) allows the emergence of anti-inflammatory and tissue-repair macrophage phenotypes.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>miR-155 acts as a molecular rheostat to determine the duration of inflammation and the initiation of repair programs in macrophages. Depending on the expression levels of miR-155, macrophages can show opposite phenotypes. TLRLs induce high expression levels of miR-155. MiR-155 targets inhibitors of TLR/cytokine receptor pathways and drive a pro-inflammatory phenotype as shown by the production of TNF, IL-1&#946;, IL-6, and chemokines. In addition, high miR-155 levels prevent a phenotypic switch to anti-inflammatory/repair macrophages by targeting (i) IL-13R&#945;, thus decreasing STAT6 activation and expression of STAT6-dependent mediators, e.g., collagen production, inducing CCL18; (ii) TGF&#946; signaling molecule SMAD2, and the transcription factor LXR&#945;, thus maintaining low levels of resolution/repair mediators, e.g., TGF&#946;, Arg2. Glucocorticoid and IL-10 override miR-155-induced phenotype by inhibiting its expression. The chronicity of synovial inflammation may be mediated by persistently high expression levels of miR-155 observed in synovial macrophages. Direct miR-155 targets are marked in bold font. TLR, toll-like receptors; IL-13R&#945;, interleukin-13 receptor alpha; TGF&#946;, transforming growth factor beta; SMAD2, small mothers against decapentaplegic homolog 2, LXRa, liver X receptor alpha; Arg2, arginase 2; GCS, glucocorticoids.</p></caption><graphic xlink:href="fimmu-08-01932-g001"/></fig></sec><sec id="S4-2"><title>miR-155 Underlies the Activation of Monocytes and Macrophages in RA</title><p>Animal studies show that miR-155 drives experimental models of arthritis and its comorbidity, atherosclerosis (<xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B64" ref-type="bibr">64</xref>). In RA patients, blood monocytes have significantly higher copy-numbers of miR-155 than healthy controls, and the copy-number correlates strongly with disease activity score (DAS of 28 joints; DAS28) and with erythrocyte sedimentation rate; a non-specific biomarker of inflammation (<xref rid="B65" ref-type="bibr">65</xref>, <xref rid="B66" ref-type="bibr">66</xref>). The expression levels of miR-155 in patients in drug-induced remission and with low DAS were similar to levels in healthy donors, whereas levels in patients with medium and high DAS were progressively increased. The expression of miR-155 in monocytes from patients with coronary heart disease is higher than normal and correlated with expression of TNF and IL-6 (<xref rid="B67" ref-type="bibr">67</xref>), suggesting that miR-155 expression in monocytes is closely associated with the degree of inflammatory activation (<xref rid="B65" ref-type="bibr">65</xref>).</p><p>Monocytes are recruited from the blood to the synovial fluid and to the synovial membrane where monocytes differentiate locally into pro-inflammatory macrophages (<xref rid="B51" ref-type="bibr">51</xref>, <xref rid="B68" ref-type="bibr">68</xref>). This is an important step in RA progression and is mediated by locally produced chemokines (<xref rid="B69" ref-type="bibr">69</xref>). Both CD14<sup>+</sup> monocytes from synovial fluid and CD68<sup>+</sup> synovial tissue macrophages from RA patients with active disease have an activated phenotype (<xref rid="B70" ref-type="bibr">70</xref>&#8211;<xref rid="B73" ref-type="bibr">73</xref>) and produce pro-inflammatory cytokines, including TNF, IL-6, and GM-CSF that are targets for current successful RA therapies (<xref rid="B74" ref-type="bibr">74</xref>&#8211;<xref rid="B76" ref-type="bibr">76</xref>). Synovial fluid-derived monocytes can also differentiate toward osteoclasts that mediate bone erosion (<xref rid="B77" ref-type="bibr">77</xref>, <xref rid="B78" ref-type="bibr">78</xref>) and promote production of the osteoclastogenic and stromal cell-activating cytokine IL-17 by CD4<sup>+</sup> T-cells which further contributes to bone and cartilage activation (<xref rid="B70" ref-type="bibr">70</xref>&#8211;<xref rid="B72" ref-type="bibr">72</xref>). We found that miR-155 is constitutively upregulated in both RA synovial tissue macrophages and synovial fluid monocytes compared to RA blood monocytes and non-inflammatory osteoarthritis controls (<xref rid="B57" ref-type="bibr">57</xref>). We demonstrated that the increased expression of miR-155 in synovial fluid CD14<sup>+</sup> cells and synovial tissue macrophages was commensurate with reduced expression of SHIP-1, which thereby enabled their inflammatory phenotype, e.g., TNF production (<xref rid="B57" ref-type="bibr">57</xref>). In monocytes, miR-155 supports the expression of the integrin CD11a (LFA-1) that interacts with intercellular adhesion molecule-1 on endothelium and facilitates migration of monocytes into inflamed tissue (<xref rid="B79" ref-type="bibr">79</xref>). Moreover, monocyte miR-155 drives the production of inflammatory chemokines, including CCL3, CCL4, CCL5, and CCL8, and downregulates the expression of CCR2 (<xref rid="B65" ref-type="bibr">65</xref>). These findings suggest that high levels of miR-155 in pro-inflammatory macrophages in synovial fluid and synovial tissue enables chemokine production and integrin expression that recruits precursors from the circulation, and then mediates the retention of these cells at sites of inflammation by downregulating chemokine receptor expression, and finally mediates local production of pro-inflammatory cytokines. Similarly, miR-155 supports the development of advanced atherosclerotic lesions. In experimental models, miR-155, induced by inflammation and oxidized lipids, targets Bcl6 in lesional macrophages and increases CCL2 production and recruitment of monocytes to vascular walls. Thus, miR-155 deficiency in macrophages ameliorated plaque formation (<xref rid="B56" ref-type="bibr">56</xref>).</p><p>Blood and synovial fluid monocytes from RA patients are resistant to spontaneous apoptosis and to apoptosis mediated by an agonistic anti-Fas antibody, as compared to blood monocytes of healthy donors (<xref rid="B80" ref-type="bibr">80</xref>&#8211;<xref rid="B84" ref-type="bibr">84</xref>). This resistance may contribute to the persistence of inflammatory monocytes and/or macrophages and their perpetuation of joint inflammation in RA. This resistance is due to the progressive inhibition of CASP10 and APAF1 by the increasing levels of miR-155 in RA cells. This was confirmed by miR-155 overexpression in healthy CD14<sup>+</sup> cells that conferred resistance to spontaneous apoptosis (<xref rid="B84" ref-type="bibr">84</xref>). <italic>In vitro</italic>, mimicking the high expression levels of miR-155 in myeloid cells of patients with RA and cardiovascular disease by enforced expression of miR-155 in healthy human monocytes/macrophages demonstrated that miR-155 triggers the spontaneous production of several pro-inflammatory cytokines, including TNF, IL-6, IL-1&#946;, and IL-8, and decreases anti-inflammatory IL-10 production (<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B65" ref-type="bibr">65</xref>, <xref rid="B84" ref-type="bibr">84</xref>). Thus, miR-155 overexpression promotes a pro-inflammatory phenotype in monocytes/macrophages, whereas <italic>in vitro</italic> treatment of RA patients&#8217; synovial fluid CD14<sup>+</sup> cells with miR-155 antagonist de-repressed SHIP-1, inhibited the production of TNF (<xref rid="B57" ref-type="bibr">57</xref>) and restored cellular homeostasis.</p><p>Synovitis is driven by cross talk between synovial macrophages with fibroblasts (<xref rid="B10" ref-type="bibr">10</xref>) and emerging evidence suggests that miRNAs packaged into macrophage-derived exosomes regulate the function of adjacent cells, including fibroblasts. This has yet to be formally established is human synovial macrophages and fibroblasts; however, an elegant paper by Wang et al. showed that, upon cardiac injury, macrophages secrete miR-155-enriched exosomes that are absorbed by cardiac fibroblasts. miR-155 is released into the fibroblasts cytoplasm, inhibits SOCS-1, and enhances production of pro-inflammatory mediators, including IL-6. Administration of macrophage-derived exosomes containing miR-155 into miR-155-deficient mice exacerbates myocardial infarction (<xref rid="B85" ref-type="bibr">85</xref>). Thus, it would be interesting to reveal the contribution of macrophage-derived miR-155 to the pathogenic phenotype of RA synovial fibroblasts.</p><p>In summary, sustained high levels of miR-155 in RA patients&#8217; synovial monocytes and synovial tissue macrophages drive their pro-inflammatory activation and prevent the switch to anti-inflammatory/repair phenotypes, thus preclude resolution of inflammation and initiation of repair (Figure <xref ref-type="fig" rid="F2">2</xref>).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>miR-155 regulates pro-inflammatory activation of monocytes/macrophages (pink) and dendritic cells (DCs) (blue). Inflammatory mediators that induce miR-155 expression in innate cells, include LPS, TNF, IFN&#946;, PAMPs, and DAMPs, while IL-10, GCS, and resolvins inhibit miR-155 expression. miR-155 promotes monocyte recruitment into inflamed tissue by the induction of appropriate chemokines, and then retains them by then downregulating CCR2 and inhibits their apoptosis by targeting APAF1 and CASP10. miR-155 drives inflammatory cytokine production by targeting SHIP-1, SOCS-1, and Bcl6. miR-155 represses the development of anti-inflammatory and repair macrophage phenotypes by targeting IL-13R&#945;, LXR&#945;, and the TGF&#946;-signaling molecule SMAD2. In myeloid DCs, miR-155 targets PU.1 and decreases the endocytic function of DCs by downregulating DC-SIGN while supporting maturation of DCs and their T-cell stimulatory activity by targeting SOCS-1/SHIP-1 and c-fos. miR-155 limits plasmocytoid DC activation by decreasing type I IFN production by targeting TAB 2. Direct targets are marked in bold font. LPS, lipopolysaccharides; TNF, tumor necrosis factor; IFN, interferon; DAMPs, danger-associated molecular pattern; CCR2, C&#8211;C chemokine receptor type 2; PU.1: Spi-1 proto-oncogene; hematopoietic transcription factor PU.1; CCL, CC chemokine ligands; SHIP-1, phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1; SOCS-1, suppressor of cytokine signaling 1; TAB 2, TGF-beta activated kinase 1/MAP3K7 binding protein 2; APAF1, apoptotic peptidase activating factor 1; CASP10, caspase 10; TGF-&#946;, transforming growth factor beta; IL, interleukin; DC-SIGN, DC-specific C-type lectin GCS, glucocorticoids.</p></caption><graphic xlink:href="fimmu-08-01932-g002"/></fig></sec><sec id="S4-3"><title>miR-155 Regulates Dendritic Cells&#8217; (DCs) Maturation</title><p>Dendritic cells are key innate regulators of the adaptive immune response by activating antigen-specific T-cells. They have an important homeostatic function by either mounting an immune response against pathogens or by inducing tolerance to self-antigens. To induce tolerance, DCs activate regulatory T-cells and/or induce anergy of antigen-specific effector T-cells; thereby terminating an immune response and preventing autoimmunity (<xref rid="B86" ref-type="bibr">86</xref>, <xref rid="B87" ref-type="bibr">87</xref>). Mouse and human DCs consist of developmentally and functionally distinct DC subsets regulated by a network of cytokines and transcriptional factors (<xref rid="B88" ref-type="bibr">88</xref>). Upon stimulation with PAMPs/DAMPs DCs undergo a maturation process which is characterized by functional changes including decreased pathogen binding/endocytic activity, increased cytokine production and enhanced antigen presentation (<xref rid="B89" ref-type="bibr">89</xref>, <xref rid="B90" ref-type="bibr">90</xref>). miRNA networks act at checkpoints during the development, differentiation and activation of DC subsets (<xref rid="B88" ref-type="bibr">88</xref>). miR-155 is dispensable for DC differentiation but is an important regulator of DC activation; mice deficient in miR-155 have normal numbers of CD8a<sup>+</sup>cDCs, CD8a<sup>&#8722;</sup>cDCs, and pDCs (<xref rid="B91" ref-type="bibr">91</xref>); however, miR-155 is readily induced in mouse and human DCs following TLR stimulation (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B92" ref-type="bibr">92</xref>, <xref rid="B93" ref-type="bibr">93</xref>). TLR stimulation activates two cellular pathways resulting in DC maturation; MyD88-IRAK-TRAF6 and TRIF-IRF3-IFN&#945;, and both are required for optimal NF-&#954;B activation, expression of co-stimulatory molecules, and the production of cytokines, such as IL-1&#946; or IL-12 (<xref rid="B94" ref-type="bibr">94</xref>, <xref rid="B95" ref-type="bibr">95</xref>). miR-155 regulates the switch from the endocytic function to co-stimulatory/activatory function during DC maturation. miR-155 reduces the capacity of DCs to bind pathogens by downregulation of DC-SIGN <italic>via</italic> inhibition of transcription factor PU.1 (<xref rid="B93" ref-type="bibr">93</xref>), while enhancing cytokine production (<xref rid="B91" ref-type="bibr">91</xref>, <xref rid="B96" ref-type="bibr">96</xref>, <xref rid="B97" ref-type="bibr">97</xref>). Studies show that miR-155<sup>&#8722;/&#8722;</sup> DCs exhibit lower levels of MHC class II and co-stimulatory molecules (CD80, CD40), and a decrease in <italic>IL1</italic>&#946;, <italic>TNF, IL12</italic>, and <italic>IL6</italic> expression upon TLR-induced maturation compared to wild-type DCs, and they demonstrate a significantly lower ability to induce effector T-cells (<xref rid="B91" ref-type="bibr">91</xref>, <xref rid="B98" ref-type="bibr">98</xref>). This may be mediated by miR-155 inhibition of c-fos, continued expression of which was shown to be detrimental for DC maturation (<xref rid="B91" ref-type="bibr">91</xref>). Similarly, inhibition of miR-155 in human monocyte-derived DCs caused a reduction in IL-12p70 production (<xref rid="B97" ref-type="bibr">97</xref>) whereas overexpression of miR-155 in mature DCs enhanced <italic>IL12p70</italic> expression, leading to higher levels of IFN-&#947; being released by cocultured natural killer cells (<xref rid="B97" ref-type="bibr">97</xref>). It was proposed that miR-155 mediated these activatory functions of DCs through epigenetic regulation of SHIP-1 and SOCS-1 in a similar manner as in macrophages (<xref rid="B96" ref-type="bibr">96</xref>, <xref rid="B97" ref-type="bibr">97</xref>).</p><p>Interestingly, miR-155 may terminate some DC functions by targeting TAB 2, a key adaptor molecule in the TLR/IL-1 pathway. These include termination of type I IFN or IL-1&#946; production induced by TLR7- or LPS-mediated human monocyte-derived DC activation, respectively (<xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B92" ref-type="bibr">92</xref>). This discrepancy requires further investigation, but the nature of the stimulatory factor and the abundance of specific target at precise time&#8211;points during DC activation may determine whether miR-155 supports or terminates DC activation.</p></sec><sec id="S4-4"><title>The Role of miR-155 in RA DC Activation</title><p>Rheumatoid arthritis peripheral blood, synovial fluid and synovial tissue DCs, in particular CD1c<sup>+</sup> and monocyte-derived populations, show a constitutively activated phenotype by their increased expression of co-stimulatory molecules, cytokines (e.g., <italic>IL6</italic>) and their ability to activate autologous T-cells (<xref rid="B99" ref-type="bibr">99</xref>&#8211;<xref rid="B102" ref-type="bibr">102</xref>). It was shown recently that high levels of miRNA-34a that lead to repression of Axl, an inhibitor of DC activation, contribute to the activated phenotype of circulating and synovial CD1c<sup>+</sup> in RA (<xref rid="B100" ref-type="bibr">100</xref>). The involvement of miR-155 to this phenotype is unknown. However, a role for DC miR-155 in driving experimental autoimmunity was shown by Lind et al. (<xref rid="B96" ref-type="bibr">96</xref>) in a model of diabetes in which self-antigen-pulsed, TLR-matured DCs lacking miR-155 have an impaired ability to break immune tolerance, while the transfer of self-antigen-pulsed DCs overexpressing miR-155 was sufficient to break tolerance even in the absence of TLR stimuli (<xref rid="B96" ref-type="bibr">96</xref>).</p></sec></sec><sec id="S5"><title>miR-155 Functions in Adaptive Immune Cells and is Deregulated in RA</title><p>Several lines of evidence support the role of miR-155 in T- and B-cell differentiation. miR-155 controls both effector and regulatory T-cell function (<xref rid="B103" ref-type="bibr">103</xref>) and regulates B-cell proliferation, germinal center formation, and antibody production (<xref rid="B104" ref-type="bibr">104</xref>). If aberrantly expressed, miR-155 contributes to initiation and progression of malignancies of B-cells and to autoimmunity.</p><sec id="S5-1"><title>miR-155 Controls B-Cell Proliferation</title><p>miR-155 is highly expressed in human B-cell lymphomas, especially in large B-cell lymphomas, Hodgkin lymphomas, and certain types of Burkitt lymphomas (<xref rid="B104" ref-type="bibr">104</xref>). Transgenic mice expressing miR-155 under the control of E&#956; enhancer and VH promoter (E&#956;-miR-155) develop aberrant accumulation of <italic>pre-B-cells</italic> leading to the development of acute lymphoma. These cells have commensurately decreased expression of miR-155 targets, e.g., SHIP-1 and CCAAT enhancer-binding protein beta (C/EBPbeta), which in B-cells have anti-inflammatory and anti-proliferative functions (<xref rid="B105" ref-type="bibr">105</xref>, <xref rid="B106" ref-type="bibr">106</xref>). miR-155 may promote survival and proliferation of <italic>na&#239;ve B cells</italic> in E&#956;-miR-155 mice by targeting co-repressor partners Hdac4 (directly) and Bcl6 (indirectly), and their reduction leads to de-repression of Bcl6 targets, e.g., inhibitor of differentiation-2, IL-6, cMyc, Cyclin D1, and Mip1&#945;/ccl3; all of which promote cell survival and proliferation. Importantly, meta-analysis of microarray data from diffuse large B-cell lymphoma patients found that miR-155 expression correlated negatively with Bcl6 and Hdac4 expression, strongly supporting the role of the miR-155/Bcl6/Hdac4 pathway in the pathogenesis of human leukemias (<xref rid="B107" ref-type="bibr">107</xref>). miR-155 also regulates proliferation of <italic>mature B-cells</italic> in germinal centers by interfering with TGF-&#946; signaling. TGF-&#946;1 secreted in secondary lymphoid organs limits mature B-cell proliferation to maintain immune-system homeostasis. miR-155 represses the TGF-&#946; signaling molecule SMAD5, resulting in defective expression of the cell-cycle inhibitor p15/p21 (<xref rid="B108" ref-type="bibr">108</xref>) and allowing B-cells unhindered progress through the cell-cycle.</p><p>Systemic delivery of antisense miR-155, encapsulated in polymer nanoparticles, inhibited miR-155 and slowed the growth of pre-B-cell tumors <italic>in vivo</italic>, confirming that miR-155 is an important regulator of B-cell proliferation, and this may be a promising therapeutic option for lymphoma or leukemia (<xref rid="B109" ref-type="bibr">109</xref>).</p></sec><sec id="S5-2"><title>miR-155 Controls Antibody Production by B-Cells</title><p>A critical stage of effector B-cell development is represented by germinal center (GC) formation. These structures develop when mature na&#239;ve B-cells encounter cognate antigen in the secondary lymphoid organs during which the B-cells undergo somatic hyper-mutation of their immunoglobulin variable region genes and class-switch recombination. Emerging B-cells that express high-affinity antibody further differentiate into plasma cells and memory B-cells (<xref rid="B110" ref-type="bibr">110</xref>). B-cells also contribute to the immune response by acting as antigen-presenting cells and fuel inflammation by releasing a wide range of cytokine and chemokines (<xref rid="B10" ref-type="bibr">10</xref>). Thai and co-workers demonstrated that miR-155 plays an essential role in the regulation of GC formation. They found that miR-155-deficient mice had greatly reduced GC formation that was due to reduced production of TNF and LT&#945;; obligate cytokines for GC neogenesis, by B-cells in response to antigen-ligation of the B-cell receptor (<xref rid="B103" ref-type="bibr">103</xref>). In support of a pivotal role for miR-155 in B-cell activation, chronic lymphocytic leukemia (CCL) B-cells that expressed high miR-155, demonstrated miR-155-dependent increased activation (calcium flux) induced by BCR ligation (<xref rid="B111" ref-type="bibr">111</xref>). The <italic>in vivo</italic> antibody response of miR-155-deficient mice showed significantly reduced concentration of IgM and isotype-switched antigen-specific antibody class production (<xref rid="B98" ref-type="bibr">98</xref>, <xref rid="B112" ref-type="bibr">112</xref>). Mechanistic studies by Vigorito et al. (<xref rid="B112" ref-type="bibr">112</xref>) showed that miR-155 can directly target PU.1 mRNA <italic>via</italic> a predicted miR-155-binding site in the 3&#8242; UTR, and that miR-155-deficient B-cells had increased PU.1 expression. Enforced expression of PU.1 in wild-type primary B-cells led to a reduction in the proportion of IgG1-expressing cells upon stimulation (<xref rid="B112" ref-type="bibr">112</xref>, <xref rid="B113" ref-type="bibr">113</xref>). Mechanistically, miR-155 reduces PU.1 expression that leads to the downregulation of Pax5, a PU.1-dependent inhibitor of B-cell activation. This enables plasma cell differentiation along with the expression of other genes involved in B/T cellular interactions (e.g., Sema4a, Sema4b, Sema7a, and CD300If) facilitating antibody production (<xref rid="B114" ref-type="bibr">114</xref>).</p><p>miR-155 can also regulate the antigen-presenting function of B-cells. miR-155 targets the 3&#8242;UTR of CD1d in B-cells (<xref rid="B115" ref-type="bibr">115</xref>). Therefore, upregulation of miR-155 in B-cells, e.g., in chronic inflammation, can repress CD1d leading to impaired lipid-antigen presentation by B-cells to invariant natural killer cells. This causes a breach of tolerance as shown by CD1d deficiency exacerbating lupus nephritis in the pristine-induced model (<xref rid="B115" ref-type="bibr">115</xref>).</p><p>Of additional relevance to autoimmune disease, miR-155 modulates the B-cell response to immune complexes. The low-affinity IgG inhibitory receptor Fc&#947;RIIB (Fc&#947; receptor IIB) is key in terminating proliferative signals delivered by autoantigen-containing immune complexes by activating SHIP-1. Thai et al. showed that miR-155 can downregulate SHIP-1 and permit immune-complex-induced pathology in the Fas<sup>lpr</sup> model of autoimmune lupus (<xref rid="B113" ref-type="bibr">113</xref>), and this may also be relevant to the signaling of the immune complexes in RA.</p></sec><sec id="S5-3"><title>The Role of miR-155 in RA B-Cells</title><p>The onset of RA is preceded by preclinical immunological changes, e.g., the production of anti-citrullinated peptides antibodies (anti-CCP/ACPA) and rheumatoid factor, which reflect the loss of immunological tolerance to self-antigens (<xref rid="B116" ref-type="bibr">116</xref>), and this places B-cells at the center of RA pathogenesis. This is confirmed by the efficacy of B-cell depletion therapy in RA patients (<xref rid="B117" ref-type="bibr">117</xref>). The proportion of B-cell subsets is altered in the blood of RA patients (<xref rid="B118" ref-type="bibr">118</xref>, <xref rid="B119" ref-type="bibr">119</xref>) with higher percentages and absolute numbers of na&#239;ve B-cells at the onset of disease, and increased proportions of double-negative (IgD<sup>&#8722;</sup>/CD27<sup>&#8722;</sup>) memory B-cells and plasmablasts in patients with established RA (<xref rid="B120" ref-type="bibr">120</xref>).</p><p>As previously stated, miR-155 was first described as an important epigenetic regulator of antibody synthesis (<xref rid="B98" ref-type="bibr">98</xref>, <xref rid="B112" ref-type="bibr">112</xref>). In experimental models of arthritis, the production of anti-collagen antibodies was significantly decreased in miR-155-deficient mice compared to wild type (<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B64" ref-type="bibr">64</xref>), and these mice did not develop arthritis. In RA patients, we found that the expression of miR-155 in B-cells is increased and is maximal during the early phase of disease. This increase is predominant in double-negative (IgD<sup>&#8722;</sup>/CD27<sup>&#8722;</sup>) memory B-cells (<xref rid="B121" ref-type="bibr">121</xref>), and occurs in ACPA<sup>+</sup> but not ACPA<sup>&#8722;</sup> RA patients suggesting a role in autoantibody production. The IgD<sup>&#8722;</sup>/CD27<sup>&#8722;</sup> B-cell population is increased in other autoimmune diseases, including SLE (<xref rid="B122" ref-type="bibr">122</xref>, <xref rid="B123" ref-type="bibr">123</xref>) and is important for IgG<sup>+</sup> plasmablast generation (<xref rid="B124" ref-type="bibr">124</xref>). In a study of paired peripheral blood&#8211;synovial fluid samples from RA patients, miR-155 expression was higher in B-cells from the synovium compared with B-cells from blood. Mediators, including IL-6, BAFF, IgM, CD40L, and IL-21 were increased in synovial fluid, and these were able to upregulate miR-155 expression in B cells <italic>in vitro</italic>. In addition, <italic>in situ</italic> hybridization revealed that most of the resident synovial tissue CD20<sup>+</sup> cells in germinal-center-like follicles were miR-155 positive. Commensurate with the increased miR-155 expression, synovial fluid-derived B-cells of RA patients showed reduced expression of the miR-155 target PU.1 in ACPA<sup>+</sup> compared to ACPA<sup>&#8722;</sup> patients, and a reduced proportion of PU.1<sup>+</sup> cells among the resident CD20<sup>+</sup> cells in synovial follicles (<xref rid="B121" ref-type="bibr">121</xref>). Inhibition of endogenous miR-155 in RA B-cells led to the restoration of PU.1 expression and inhibition of antibody production (<xref rid="B121" ref-type="bibr">121</xref>) suggesting a key role of miR-155 in autoantibody production by B-cells in RA. Commensurate with this, the expression of miR-155 in circulating B-cells of ACPA<sup>+</sup> RA is significantly higher than that of similarly inflamed patients with psoriatic arthritis (PsA), in which B-cells are minimally involved in pathogenesis (<xref rid="B121" ref-type="bibr">121</xref>). In addition, the expression of miR-155 in circulating B-cells is particularly high in RA patients with follicular synovitis; which is a prognostic factor for poor treatment response (<xref rid="B125" ref-type="bibr">125</xref>). Thus, miR-155 expression in RA circulating B-cells can serve as a biomarker of B cell activation and lymphoid/follicular synovitis among the three RA synovial pathotypes identified (myeloid, lymphoid/follicular, and fibroid) (<xref rid="B126" ref-type="bibr">126</xref>). A summary of miR-155 function in B-cells is presented on Figure <xref ref-type="fig" rid="F3">3</xref>.</p><fig id="F3" position="float"><label>Figure 3</label><caption><p>miR-155 supports B-cell proliferation and antibody production. Several cytokines and TLR-ligands can induce miR-155 expression in B-cells. These include LPS, IL-6, IL-21, CD40L, IFN-&#945;, and BAFF, while TGF&#946; inhibits miR-155 expression. By targeting SHIP-1, C/EBP&#946;, the Hdac4/Bcl6 complex, and the TGF&#946; signaling molecule SMAD5, miR-155 drives proliferation and resistance to apoptosis of B-cells. miR-155, by epigenetic regulation of PU.1, is indispensable for B-cell maturation, migration, interaction with T-cells, and antibody production. Moreover, miR-155 regulates the surface expression of CD1d on B-cells, influencing the cellular cross talk with invariant NK T-cells. Direct targets are marked in bold font. LPS, lipopolysaccharides<italic>;</italic> IL, interleukin; TLR, toll-like receptor; Bcl, B-cell lymphoma; SMAD5, small mother against decapentaplegic 5; CD, cluster designation; PU.1, Spi-1 Proto-Oncogene; Sema, semaforin; NK, natural killer; BAFF, B-cell activating factor; CD40L, CD40 ligand. TGF-&#946;, transforming growth factor beta; SHIP-1, phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1; Bcl6, B-cell lymphoma; HDAC4; histone deacetylase 4; C/EBP&#946;: CCAAT/enhancer-binding protein beta; NFAM1, NFAT activating protein with ITAM motif 1; CXCR4; C&#8211;X&#8211;C chemokine receptor type 4; CCR7, C&#8211;C chemokine receptor type 7; S1Pr1, sphingosine-1-phosphate receptor 1; TNFsF4, tumor necrosis factor (ligand) superfamily, member 4; CD300lf, CMRF35-like molecule 1.</p></caption><graphic xlink:href="fimmu-08-01932-g003"/></fig></sec><sec id="S5-4"><title>miR-155 Is a Regulator of T-Cell Differentiation</title><p>In response to appropriate stimuli, CD4<sup>+</sup> T-cells can differentiate into different phenotypes that include the Th1, Th2, Th17, follicular helper T (Tfh) cells, and T-regulatory (Treg) cell lineages with distinct functions (<xref rid="B127" ref-type="bibr">127</xref>). This differentiation is influenced by cytokines and by the expression and activation of phenotype-specific transcription factors (<xref rid="B128" ref-type="bibr">128</xref>). miRNAs have been implicated in CD4<sup>+</sup> T-cell differentiation (<xref rid="B129" ref-type="bibr">129</xref>, <xref rid="B130" ref-type="bibr">130</xref>) and miR-155 is central to this process (<xref rid="B98" ref-type="bibr">98</xref>, <xref rid="B131" ref-type="bibr">131</xref>).</p><sec id="S5-4-1"><title>T-Helper 1</title><p>Rodriguez and colleagues examined the T-cell response of miR-155-deficient mice immunized with T-dependent antigen (tetanus toxin fragment C) and showed that splenocytes produced significantly reduced concentrations of IL-2 and IFN-&#947; compared to wild-type mice (<xref rid="B98" ref-type="bibr">98</xref>). An intrinsic requirement for miR-155 to Th1 development was confirmed <italic>in vitro</italic> by comparing the cytokine production by WT and miR-155<sup>&#8722;/&#8722;</sup> CD4<sup>+</sup> cells in culture following anti-CD3 and anti-CD28 stimulation, which demonstrated reduced IFN&#947; production by miR-155<sup>&#8722;/&#8722;</sup> cells (<xref rid="B98" ref-type="bibr">98</xref>). In keeping with these observations, Banerjee and co-workers showed that overexpression of miR-155 in activated CD4<sup>+</sup> T-cells promoted Th1 differentiation by targeting IFN-&#947;R&#945; thereby decreasing the sensitivity of Th1&#8201;cells to the anti-proliferative effects of IFN-&#947; (<xref rid="B131" ref-type="bibr">131</xref>).</p></sec><sec id="S5-4-2"><title>Th2</title><p>miR-155 was initially described as a negative regulator of Th2 commitment through the repression of its target c-Maf, which is an IL-4 promoter transactivator (<xref rid="B98" ref-type="bibr">98</xref>). CD4<sup>+</sup> T-cells from miR-155-deficient mice exhibit preferential Th2 differentiation upon activation (<xref rid="B132" ref-type="bibr">132</xref>&#8211;<xref rid="B134" ref-type="bibr">134</xref>). miR-155-deficient mice have an age-dependent increased number of Th2 cells and develop spontaneous airway remodeling due to the action of Th2 cytokines (<xref rid="B98" ref-type="bibr">98</xref>). In keeping with this, we recently reported that miR-155-deficient mice are susceptible to exacerbated bleomycin-induced lung fibrosis (<xref rid="B36" ref-type="bibr">36</xref>). In contrast, Malmhall et al., using an antigen-induced asthma model, observed that miR-155-deficient mice had decreased activation of Th2 cells and decreased production of IL-4, IL-5, and IL-13, decrease lung eosinophilia and fewer physiological changes compared with wild-type mice (<xref rid="B135" ref-type="bibr">135</xref>). The potential inhibition of Th2 development was not associated with c-Maf changes but with depression of PU.1 that negatively regulates the expression of GATA3, the key transcription factor for Th2 cell function. Similarly, Okoye et al. described a Th2-cell-selective role for miR-155 in the development of an allergic airway model. They demonstrated that miR-155 inhibits the expression of sphingosine-1-phosphate receptor 1, which is required for lymphocyte egress from lymphoid organs, thus mice with miR-155<sup>&#8722;/&#8722;</sup> T-cells had reduced airway pathology (<xref rid="B136" ref-type="bibr">136</xref>). This suggests that the miR-155 may highlight different roles for Th2 responses in acute allergic inflammation compared with fibrosis. It is possible that resident tissue memory T-cells are more involved in age-related and bleomycin-induced chronic lung remodeling, whereas recently activated recruited T-cells are more involved in acute airway inflammation.</p></sec><sec id="S5-4-3"><title>Th17</title><p>Th17 lymphocytes have higher expression levels of miR-155 compared with other T-cell subset lineages (<xref rid="B137" ref-type="bibr">137</xref>). miR-155 is upregulated in Th17&#8201;cells by STAT3, IRF-4 and ROR&#947;t and supports the development of Th17 by inhibiting its epigenetic target Jarid2, which itself is an epigenetic suppressor of Il22, Il10, Il9, and Atf3 (<xref rid="B137" ref-type="bibr">137</xref>), and by suppressing SOCS-1, thereby facilitating IL-6/STAT3 signaling (<xref rid="B138" ref-type="bibr">138</xref>). Accordingly, miR-155-deficient mice have substantially reduced numbers of Th17&#8201;cells as demonstrated by reduced expression of IL-17A (<xref rid="B139" ref-type="bibr">139</xref>), IL-22, IL-6, and IL-23R (<xref rid="B64" ref-type="bibr">64</xref>, <xref rid="B139" ref-type="bibr">139</xref>&#8211;<xref rid="B141" ref-type="bibr">141</xref>).</p></sec><sec id="S5-4-4"><title>Follicular T-Helper Cells (Tfh)</title><p>Follicular T-helper cells cells are key in GC formation and antibody production by providing help to B-cells in secondary lymphoid tissue. Elegant work led by Tang showed that miR-155 is indispensable in the development of Tfh. Using CD4<sup>+</sup>-specific miR-155-deficient mice, the authors showed reduced levels of Tfh (CXCR5<sup>+</sup>PD1<sup>+</sup> Bcl6<sup>+</sup>) and consequently less-developed GCs and reduced antigen-specific antibody production in a variety of immunization schedules. Silencing of two proteins, Fosl2 (a component of AP1) and to a lesser extent Peli1 (E3 ubiquitin ligase) in miR-155<sup>&#8722;/&#8722;</sup> CD4<sup>+</sup> T-cells, resulted in improved development of Tfh cells following immunization, suggesting that miR-155 mediates Tfh differentiation by downregulating these two targets (<xref rid="B142" ref-type="bibr">142</xref>).</p></sec><sec id="S5-4-5"><title>Regulatory T-Cells</title><p>There is abundant evidence that miR-155 can promote the development of Tregs. These cells are important to maintain immunological tolerance by limiting pathogenic Th-cell responses. Tregs are dependent on IL-2/STAT5 signaling and are characterized by the expression of Foxp3. This transcription factor induces miR-155 which then upregulates STAT5 phosphorylation by its epigenetic blockade of SOCS-1-mediated inhibition of STAT5. miR-155-deficient mice have reduced numbers of Tregs in the thymus and in peripheral blood due to attenuated IL-2 signaling by de-repressed SOCS-1 (<xref rid="B143" ref-type="bibr">143</xref>, <xref rid="B144" ref-type="bibr">144</xref>). Cytotoxic T-lymphocyte antigen 4 (CTLA-4), which is an effector molecule of Tregs that binds to CD28 and limits the activation of effector T-cells, is a putative mRNA target of miR-155 (<xref rid="B143" ref-type="bibr">143</xref>, <xref rid="B145" ref-type="bibr">145</xref>). However, Tregs from miR-155-deficient mice express normal levels of CTLA-4 suggesting that it is not under the epigenetic control of miR-155, at least in Tregs in mice. In contrast, Sonkoly et al. showed that miR-155 targets CTLA-4 mRNA in human effector T-cells. This group observed an increased level of miR-155 and decreased level of CTLA-4 in effector T-cells of patients with atopic dermatitis, suggesting that miR-155 inhibition of CTLA-4 contribute to activation of effector T-cells in the skin (<xref rid="B146" ref-type="bibr">146</xref>). Thus, miR-155/CTLA-4 interactions might be cell-type and species-specific.</p></sec><sec id="S5-4-6"><title>CD8<sup>+</sup></title><p>Deletion of Dicer in cytotoxic CD8<sup>+</sup> T-cells causes an impaired immune response to pathogens (<xref rid="B147" ref-type="bibr">147</xref>). Gracias et al. (<xref rid="B148" ref-type="bibr">148</xref>) found miR-155 upregulated in primary effector and effector memory CD8<sup>+</sup> T-cells as compared to naive and central memory CD8<sup>+</sup> cells. Antiviral CD8<sup>+</sup> T-cell responses and viral clearance were impaired in miR-155-deficient mice, while miR-155 overexpression augmented antiviral CD8<sup>+</sup> T-cell responses <italic>in vivo</italic>. Increased miR-155 inhibited the type I interferon response in CD8<sup>+</sup> cells while miR-155-deficient CD8<sup>+</sup> T-cells had enhanced type I interferon signaling and were more susceptible to IFNs antiproliferative effect. Inhibition of type I interferon-associated transcription factors STAT1 or IRF7 resulted in enhanced responses of miR-155-deficient CD8<sup>+</sup> T-cells to viral infection <italic>in vivo</italic> (<xref rid="B148" ref-type="bibr">148</xref>). This suggests that miR-155 maintains proliferation of CD8<sup>+</sup> in response to viral antigen by downregulation of STAT1/IRF7.</p></sec></sec><sec id="S5-5"><title>The Role of miR-155 in T Cells in RA</title><p>In experimental arthritis, miR-155-deficiency affects Th17&#8201;cell polarization. Production of IL-17 and IL-22 are significantly reduced in miR-155-deficient mice compared to wild type (<xref rid="B64" ref-type="bibr">64</xref>). Smigielska-Czepiel and colleagues provided important insight into the differential expression of specific miRNAs in human T-cell subsets, especially naive and memory T-cells in peripheral blood and synovial fluid in RA patients (<xref rid="B149" ref-type="bibr">149</xref>). Synovial fluid T-cells are predominantly memory T-cells (<xref rid="B150" ref-type="bibr">150</xref>) and are characterized by high expression of miR-155 compared with naive T-cells (<xref rid="B149" ref-type="bibr">149</xref>), thus miR-155 in this compartment may support local production of IL-17 and IFN&#947; by autoreactive T-cells.</p><p>Despite the presence of many Tregs in the synovial fluid of RA (<xref rid="B151" ref-type="bibr">151</xref>&#8211;<xref rid="B153" ref-type="bibr">153</xref>), joint inflammation persists in most patients regardless of the treatment regimen. One interpretation is that there is a functional defect in these Tregs, e.g., due to inhibition of Foxp3 by TNF (<xref rid="B154" ref-type="bibr">154</xref>) that is in high concentration in synovial fluid; or that the effector T-cells are resistant to the regulatory action of Tregs (<xref rid="B155" ref-type="bibr">155</xref>). Blood Tregs from RA patients have significantly lower expression of miR-155 than healthy controls (<xref rid="B156" ref-type="bibr">156</xref>). However, correcting this expression by enforcing exogenous miR-155 in RA Tregs <italic>in vitro</italic> enhanced their production of TNF, IL-17, and IFN&#947; after 24&#8201;h upon stimulation with anti-CD3/CD28 (<xref rid="B156" ref-type="bibr">156</xref>). This suggests that altering the expression of miR-155 alone is not sufficient to restore the immunosuppressive function of RA Tregs but promotes pathogenic cytokine production instead.</p><p>In summary, miR-155 is indispensable for activation of Th1, Th17, Tfh, CD8<sup>+</sup>, and Treg while inhibiting Th2 (Figure <xref ref-type="fig" rid="F4">4</xref>). Sustained high expression of miR-155 in synovial effector T-cells may contribute to chronic production of IFN&#947;, IL-17 and facilitate differentiation of T-cells toward Tfh cells in RA.</p><fig id="F4" position="float"><label>Figure 4</label><caption><p>miR-155 drives differentiation of T-helper 1 (Th1), Th17, Tfh and is indispensable for the function of Tregs. miR-155 has multiple effects on T-cell function. miR-155 promotes: Th1 by targeting IFNR&#945;; Th17 by targeting Jarid2 and SOCS-1; and follicular helper T-cells (Tfh) by targeting Fosl2 and Peli. Mir-155 supports the function of regulatory T-cells (Treg) by targeting SOCS-1 that enables IL-2 signaling. miR-155 regulates Th2 development and function; e.g., inhibiting development by targeting c-maf; a key transcription factor for IL-4 and regulating an egress of T cells from the lymph nodes by targeting S1PR1. Direct targets are marked in bold font. TGF, transforming growth factor; IL, interleukin; TCR, T cell receptor; IFN, interferon; SOCS-1, suppressor of cytokine signaling 1; STAT, signal transducer and activator of transcription; SHIP, phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1; c-maf, transcription factor Maf; reg, regulatory; JARID2, Jumonji, AT rich interactive domain 2; SP1R1, sphingosine-1-phosphate receptor-1.</p></caption><graphic xlink:href="fimmu-08-01932-g004"/></fig></sec></sec><sec id="S6"><title>Is There Therapeutic Potential in Targeting miR-155 in Arthritis?</title><p>The literature and our own experimental findings summarized in this review indicate that miR-155 is a key mediator of chronic activation of innate and adaptive immunity in RA. Its contribution to RA pathogenesis might be more profound than in other forms of inflammatory arthritis such as PsA due to the involvement of miR-155 in driving autoantibody production in RA. A cross-sectional analysis of RA patients with different clinical responses to treatments revealed that miR-155 expression becomes reduced in the monocytes of RA patients who responded well to conventional disease-modifying anti-rheumatic drugs (e.g., methotrexate) or to biological DMARDs (<xref rid="B65" ref-type="bibr">65</xref>). Consistent with this, there are prospective studies in psoriasis patients showing that the expression levels of miR-155 in PBMCs decreased upon successful treatment with methotrexate as compared to pre-treatment levels (<xref rid="B157" ref-type="bibr">157</xref>). These observations suggest that a reduction of high to normal expression of miR-155 reflects a good clinical response to therapies that reduce inflammation (Figure <xref ref-type="fig" rid="F5">5</xref>). However, the effects of current anti-inflammatory (e.g., <italic>anti TNF, anti-IL-6R</italic>) or anti-adaptive immunity (e.g., <italic>CTLA-4</italic>) therapies on miR-155 expression in B-cells and Th17&#8201;cells still needs to be investigated in prospective studies.</p><fig id="F5" position="float"><label>Figure 5</label><caption><p>Regulation of miR-155 expression in RA. Initiators of inflammation, e.g., PAMPs and DAMPs increase miR-155 expression. Homeostatic resolution is controlled by anti-inflammatory mediators that act in part by decreasing miR-155 expression (e.g., IL-10, GCS, TTP, resolvins) or counterbalancing its function, e.g., miR-146. In rheumatoid arthritis (RA), there is persistent inflammation and activation of adaptive immunity which maintain high expression levels of miR-155 that lock the immune system in an activatory state. A successful response to treatment (reduced systemic and synovial inflammation) in RA patients is associated with a reduction of miR-155 expression (at least in monocytes). PAMPs, pathogen-associated molecular patterns; DAMPs, damage-associated molecular patterns; GCS, glucocorticoids; TTP, tristetraproline; cDMARD, conventional disease-modifying anti-rheumatic drugs; TNFi, TNF inhibitors.</p></caption><graphic xlink:href="fimmu-08-01932-g005"/></fig><p>Chronic inflammation and continuous activation of adaptive immunity generate pro-inflammatory cytokines and autoantibodies that fuel high levels of miR-155 expression thus locking the immune system into an activatory state. Targeting miRNAs has proven to be a useful therapeutic option in infectious diseases, cancer and recently in tendinopathy (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>). The most clinically advanced example of targeting miRNA is neutralization of miR-122 to treat hepatitis C infections (HCV) that is currently in phase IIa clinical trials. miR-122 supports the replication of HCV (<xref rid="B158" ref-type="bibr">158</xref>) and treatment with antimiR-122 (Mirvirasen; Roche/Santaris and Regulus Therapeutics) achieved a reduction in viral titers in HCV-infected patients (<xref rid="B8" ref-type="bibr">8</xref>). Another miR-targeted therapeutic that reached clinical development is a mimic of the tumor suppressor miR-34. miR-34a targets pro-apoptotic proteins and cell-cycle inhibitors, and is downregulated in many human cancers (<xref rid="B159" ref-type="bibr">159</xref>). The miR-34 mimic MRX34 (Mirna Therapeutics), encapsulated in lipid nanoparticles, is currently being tested in several solid and hematological malignancies (<xref rid="B8" ref-type="bibr">8</xref>). We showed recently that chronic tendinopathy is driven by deregulation of the IL-33/miR-29 pathway leading to the production of pro-inflammatory mediators and collagen 3 with weak tensile strength, thus limiting effective tendon healing (<xref rid="B160" ref-type="bibr">160</xref>). The results from a randomized, blinded trial of local tendon miR-29a replacement therapy in an equine model, that closely mimics human disease, changed the collagen composition toward stronger collagen 1 and improved early tendon healing (<xref rid="B9" ref-type="bibr">9</xref>). Human trials will be conducted in the near future.</p><p>To date, the potential clinical outcome of miR-155 inhibition in arthritis is based on findings from animal models, and from <italic>ex vivo</italic> studies using RA patient-derived cells. miR-155-deficient mice are resistant to arthritis, and inhibition of miR-155 using specific antimiR in a collagen-induced arthritis model reduced the clinical onset and severity of disease (<xref rid="B161" ref-type="bibr">161</xref>). Thus, inhibiting miR-155 may represent an attractive therapeutic option. However, systemic inhibition of miR-155 may compromise its other physiological functions and lead to unwanted consequences. Experimental and clinical evidence suggest that miR-155 is indispensable for normal immunity against pathogens (<xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B103" ref-type="bibr">103</xref>). In addition, miR-155 in liver macrophages (Kupffer cells) is key in the regulation of lipid metabolism. Mir-155 regulates the expression levels of a target mRNA LXR&#945; which is a transcription factor that controls lipid metabolism and lipid efflux, thus miR-155-deficient mice have an increased level of circulating cholesterol and develop fatty liver (liver steatosis) while on a high-fat diet (<xref rid="B162" ref-type="bibr">162</xref>). Furthermore, miR-155 controls lung interstitial remodeling by regulating the proliferation and collagen production of lung fibroblasts, the repair macrophage phenotype, and the production of type 2 cytokines (<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B98" ref-type="bibr">98</xref>). miR-155-deficient mice develop spontaneous age-related lung fibrosis and exacerbated lung fibrosis associated with administration of bleomycin. The lack of miR-155 epigenetic control in these murine lung fibroblasts resembles the deregulated <italic>in vitro</italic> pro-fibrotic behavior of lung fibroblasts from patients with idiopathic pulmonary fibrosis (<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B98" ref-type="bibr">98</xref>). This suggests that a therapeutic strategy in arthritis of systemic targeting of miR-155, or pan-macrophage-specific delivery of miR-155 inhibitors <italic>via</italic> liposomes might have detrimental effects. There may be an alternative method of delivery of a miR-155-inhibitor. An elegant study led by Cheng et al. (<xref rid="B163" ref-type="bibr">163</xref>) showed that delivery of anti-miR-155 could be specifically targeted to hypoxic tissues such as tumors or inflamed tissues with an ambient low pH created by anaerobic metabolism. The authors linked antimiR-155 with a low pH-induced transmembrane structure (pHLIP). At pH less than 7, the C-terminus of pHLIP inserts across lipid bilayers and facilitates delivery of the attached antimiR-155. Inside the cell, the disulfide bond between pHLIP and antimiR-155 is reduced in the cytosol and the intracellular antimiR-155 is free to inhibit miR-155. The inflamed synovial tissue environment is hypoxic (<xref rid="B164" ref-type="bibr">164</xref>), thus this novel delivery systems could inhibit miR-155 in arthritis and avoid off-target side effects such as reduced protective immunity, fibrosis, or liver steatosis. Alternatively, enhancing activation of inhibitors of cell activation that are repressed by miR-155, e.g., SHIP-1 by specific activators might be a safer option (<xref rid="B165" ref-type="bibr">165</xref>). SHIP-1 activator (AQX-1125) has generated positive clinical data from clinical trials in COPD and allergic asthma, demonstrating a favorable safety profile and anti-inflammatory activity (<italic>trial number: NCT01954628</italic>).</p></sec><sec id="S7"><title>Future Directions</title><p>There are gaps in the identification and characterization of all direct miR-155 targets and the physiological impact of miR-155 inhibition on these targets would need to be revealed before anti-miR-155 therapy can be considered. Moreover, understanding the role of miR-155 that is naturally contained in vesicles transferred between cells in the synovium may provide insight into mechanisms of chronicity. Investigation of miR-155 in DCs and B-cells in the preclinical phase of RA (asymptomatic ACPA positive individuals) would help to dissect its role in the regulation of the breach of immunological tolerance. A biomarker for treatment responses in arthritis would be of considerable clinical value, therefore, prospective studies using cohorts of RA patients at different stages of disease would validate whether miR-155 could fulfill this additional role.</p></sec><sec id="S8"><title>Author Contributions</title><p>MK-S and SA selected the research and wrote the review. EG, CM, BT, GF, and IM selected the research.</p></sec><sec id="S9"><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> This work was supported by the ARUK Rheumatoid Arthritis Pathogenesis Centre of Excellence (RACE/20298).</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allis</surname><given-names>CD</given-names></name><name><surname>Jenuwein</surname><given-names>T</given-names></name></person-group>. <article-title>The molecular hallmarks of epigenetic control</article-title>. <source>Nat Rev Genet</source> (<year>2016</year>) <volume>17</volume>:<fpage>487</fpage>&#8211;<lpage>500</lpage>.<pub-id pub-id-type="doi">10.1038/nrg.2016.59</pub-id><?supplied-pmid 27346641?><pub-id pub-id-type="pmid">27346641</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baltimore</surname><given-names>D</given-names></name><name><surname>Boldin</surname><given-names>MP</given-names></name><name><surname>O&#8217;Connell</surname><given-names>RM</given-names></name><name><surname>Rao</surname><given-names>DS</given-names></name><name><surname>Taganov</surname><given-names>KD</given-names></name></person-group>. <article-title>MicroRNAs: new regulators of immune cell development and function</article-title>. <source>Nat Immunol</source> (<year>2008</year>) <volume>9</volume>:<fpage>839</fpage>&#8211;<lpage>45</lpage>.<pub-id pub-id-type="doi">10.1038/ni.f.209</pub-id><?supplied-pmid 18645592?><pub-id pub-id-type="pmid">18645592</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>L</given-names></name><name><surname>Hannon</surname><given-names>GJ</given-names></name></person-group>
<article-title>MicroRNAs: small RNAs with a big role in gene regulation</article-title>. <source>Nat Rev Genet</source> (<year>2004</year>) <volume>5</volume>:<fpage>522</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1038/nrg1415</pub-id><pub-id pub-id-type="pmid">15211354</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group>
<article-title>MicroRNAs</article-title>. <source>Cell</source> (<year>2004</year>) <volume>116</volume>:<fpage>281</fpage>&#8211;<lpage>97</lpage>.<pub-id pub-id-type="doi">10.1016/S0092-8674(04)00045-5</pub-id><pub-id pub-id-type="pmid">14744438</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>RC</given-names></name><name><surname>Farh</surname><given-names>KK</given-names></name><name><surname>Burge</surname><given-names>CB</given-names></name><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group>. <article-title>Most mammalian mRNAs are conserved targets of microRNAs</article-title>. <source>Genome Res</source> (<year>2009</year>) <volume>19</volume>:<fpage>92</fpage>&#8211;<lpage>105</lpage>.<pub-id pub-id-type="doi">10.1101/gr.082701.108</pub-id><?supplied-pmid 18955434?><pub-id pub-id-type="pmid">18955434</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kloosterman</surname><given-names>WP</given-names></name><name><surname>Plasterk</surname><given-names>RH</given-names></name></person-group>. <article-title>The diverse functions of microRNAs in animal development and disease</article-title>. <source>Dev Cell</source> (<year>2006</year>) <volume>11</volume>:<fpage>441</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="doi">10.1016/j.devcel.2006.09.009</pub-id><?supplied-pmid 17011485?><pub-id pub-id-type="pmid">17011485</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>A</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group>. <article-title>MicroRNAs as regulatory elements in immune system logic</article-title>. <source>Nat Rev Immunol</source> (<year>2016</year>) <volume>16</volume>:<fpage>279</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="doi">10.1038/nri.2016.40</pub-id><?supplied-pmid 27121651?><pub-id pub-id-type="pmid">27121651</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rupaimoole</surname><given-names>R</given-names></name><name><surname>Slack</surname><given-names>FJ</given-names></name></person-group>. <article-title>MicroRNA therapeutics: towards a new era for the management of cancer and other diseases</article-title>. <source>Nat Rev Drug Discov</source> (<year>2017</year>) <volume>16</volume>:<fpage>203</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="doi">10.1038/nrd.2016.246</pub-id><?supplied-pmid 28209991?><pub-id pub-id-type="pmid">28209991</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watts</surname><given-names>AE</given-names></name><name><surname>Millar</surname><given-names>NL</given-names></name><name><surname>Platt</surname><given-names>J</given-names></name><name><surname>Kitson</surname><given-names>SM</given-names></name><name><surname>Akbar</surname><given-names>M</given-names></name><name><surname>Rech</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>MicroRNA29a treatment improves early tendon injury</article-title>. <source>Mol Ther</source> (<year>2017</year>) <volume>25</volume>:<fpage>2415</fpage>&#8211;<lpage>26</lpage>.<pub-id pub-id-type="doi">10.1016/j.ymthe.2017.07.015</pub-id><?supplied-pmid 28822690?><pub-id pub-id-type="pmid">28822690</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Firestein</surname><given-names>GS</given-names></name><name><surname>McInnes</surname><given-names>IB</given-names></name></person-group>. <article-title>Immunopathogenesis of rheumatoid arthritis</article-title>. <source>Immunity</source> (<year>2017</year>) <volume>46</volume>:<fpage>183</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2017.02.006</pub-id><?supplied-pmid 28228278?><pub-id pub-id-type="pmid">28228278</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagy</surname><given-names>G</given-names></name><name><surname>van Vollenhoven</surname><given-names>RF</given-names></name></person-group>. <article-title>Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?</article-title>
<source>Arthritis Res Ther</source> (<year>2015</year>) <volume>17</volume>:<fpage>181</fpage>.<pub-id pub-id-type="doi">10.1186/s13075-015-0707-1</pub-id><?supplied-pmid 26235544?><pub-id pub-id-type="pmid">26235544</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ospelt</surname><given-names>C</given-names></name><name><surname>Gay</surname><given-names>S</given-names></name><name><surname>Klein</surname><given-names>K</given-names></name></person-group>. <article-title>Epigenetics in the pathogenesis of RA</article-title>. <source>Semin Immunopathol</source> (<year>2017</year>) <volume>39</volume>:<fpage>409</fpage>&#8211;<lpage>19</lpage>.<pub-id pub-id-type="doi">10.1007/s00281-017-0621-5</pub-id><?supplied-pmid 28324153?><pub-id pub-id-type="pmid">28324153</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>VN</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Siomi</surname><given-names>MC</given-names></name></person-group>
<article-title>Biogenesis of small RNAs in animals</article-title>. <source>Nat Rev Mol Cell Biol</source> (<year>2009</year>) <volume>10</volume>:<fpage>126</fpage>&#8211;<lpage>39</lpage>.<pub-id pub-id-type="doi">10.1038/nrm2632</pub-id><pub-id pub-id-type="pmid">19165215</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krol</surname><given-names>J</given-names></name><name><surname>Loedige</surname><given-names>I</given-names></name><name><surname>Filipowicz</surname><given-names>W</given-names></name></person-group>. <article-title>The widespread regulation of microRNA biogenesis, function and decay</article-title>. <source>Nat Rev Genet</source> (<year>2010</year>) <volume>11</volume>:<fpage>597</fpage>&#8211;<lpage>610</lpage>.<pub-id pub-id-type="doi">10.1038/nrg2843</pub-id><?supplied-pmid 20661255?><pub-id pub-id-type="pmid">20661255</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brennecke</surname><given-names>J</given-names></name><name><surname>Stark</surname><given-names>A</given-names></name><name><surname>Russell</surname><given-names>RB</given-names></name><name><surname>Cohen</surname><given-names>SM</given-names></name></person-group>. <article-title>Principles of microRNA-target recognition</article-title>. <source>PLoS Biol</source> (<year>2005</year>) <volume>3</volume>:<fpage>e85</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pbio.0030085</pub-id><?supplied-pmid 15723116?><pub-id pub-id-type="pmid">15723116</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doench</surname><given-names>JG</given-names></name><name><surname>Sharp</surname><given-names>PA</given-names></name></person-group>. <article-title>Specificity of microRNA target selection in translational repression</article-title>. <source>Genes Dev</source> (<year>2004</year>) <volume>18</volume>:<fpage>504</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="doi">10.1101/gad.1184404</pub-id><?supplied-pmid 15014042?><pub-id pub-id-type="pmid">15014042</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grimson</surname><given-names>A</given-names></name><name><surname>Farh</surname><given-names>KK</given-names></name><name><surname>Johnston</surname><given-names>WK</given-names></name><name><surname>Garrett-Engele</surname><given-names>P</given-names></name><name><surname>Lim</surname><given-names>LP</given-names></name><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group>. <article-title>MicroRNA targeting specificity in mammals: determinants beyond seed pairing</article-title>. <source>Mol Cell</source> (<year>2007</year>) <volume>27</volume>:<fpage>91</fpage>&#8211;<lpage>105</lpage>.<pub-id pub-id-type="doi">10.1016/j.molcel.2007.06.017</pub-id><?supplied-pmid 17612493?><pub-id pub-id-type="pmid">17612493</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>BP</given-names></name><name><surname>Burge</surname><given-names>CB</given-names></name><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group>. <article-title>Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets</article-title>. <source>Cell</source> (<year>2005</year>) <volume>120</volume>:<fpage>15</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1016/j.cell.2004.12.035</pub-id><?supplied-pmid 15652477?><pub-id pub-id-type="pmid">15652477</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tam</surname><given-names>W</given-names></name><name><surname>BenYehuda</surname><given-names>D</given-names></name><name><surname>Hayward</surname><given-names>WS</given-names></name></person-group>. <article-title>bic, a novel gene activated by proviral insertions in avian leukosis virus-induced lymphomas, is likely to function through its noncoding RNA</article-title>. <source>Mol Cell Biol</source> (<year>1997</year>) <volume>17</volume>:<fpage>1490</fpage>&#8211;<lpage>502</lpage>.<pub-id pub-id-type="doi">10.1128/MCB.17.3.1490</pub-id><?supplied-pmid 9032277?><pub-id pub-id-type="pmid">9032277</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tam</surname><given-names>W</given-names></name></person-group>. <article-title>Identification and characterization of human BIC, a gene on chromosome 21 that encodes a noncoding RNA</article-title>. <source>Gene</source> (<year>2001</year>) <volume>274</volume>:<fpage>157</fpage>&#8211;<lpage>67</lpage>.<pub-id pub-id-type="doi">10.1016/S0378-1119(01)00612-6</pub-id><?supplied-pmid 11675008?><pub-id pub-id-type="pmid">11675008</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lagos-Quintana</surname><given-names>M</given-names></name><name><surname>Rauhut</surname><given-names>R</given-names></name><name><surname>Yalcin</surname><given-names>A</given-names></name><name><surname>Meyer</surname><given-names>J</given-names></name><name><surname>Lendeckel</surname><given-names>W</given-names></name><name><surname>Tuschl</surname><given-names>T</given-names></name></person-group>. <article-title>Identification of tissue-specific microRNAs from mouse</article-title>. <source>Curr Biol</source> (<year>2002</year>) <volume>12</volume>:<fpage>735</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/S0960-9822(02)00809-6</pub-id><?supplied-pmid 12007417?><pub-id pub-id-type="pmid">12007417</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>CC</given-names></name><name><surname>Chen</surname><given-names>WD</given-names></name><name><surname>Shen</surname><given-names>WL</given-names></name><name><surname>Ruan</surname><given-names>CC</given-names></name><name><surname>Zhu</surname><given-names>LM</given-names></name><etal/></person-group>
<article-title>MicroRNA-155 regulates angiotensin II type 1 receptor expression and phenotypic differentiation in vascular adventitial fibroblasts</article-title>. <source>Biochem Biophys Res Commun</source> (<year>2010</year>) <volume>400</volume>:<fpage>483</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/j.bbrc.2010.08.067</pub-id><?supplied-pmid 20735984?><pub-id pub-id-type="pmid">20735984</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landgraf</surname><given-names>P</given-names></name><name><surname>Rusu</surname><given-names>M</given-names></name><name><surname>Sheridan</surname><given-names>R</given-names></name><name><surname>Sewer</surname><given-names>A</given-names></name><name><surname>Iovino</surname><given-names>N</given-names></name><name><surname>Aravin</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>A mammalian microRNA expression atlas based on small RNA library sequencing</article-title>. <source>Cell</source> (<year>2007</year>) <volume>129</volume>:<fpage>1401</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="doi">10.1016/j.cell.2007.04.040</pub-id><?supplied-pmid 17604727?><pub-id pub-id-type="pmid">17604727</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masaki</surname><given-names>S</given-names></name><name><surname>Ohtsuka</surname><given-names>R</given-names></name><name><surname>Abe</surname><given-names>Y</given-names></name><name><surname>Muta</surname><given-names>K</given-names></name><name><surname>Umemura</surname><given-names>T</given-names></name></person-group>. <article-title>Expression patterns of microRNAs 155 and 451 during normal human erythropoiesis</article-title>. <source>Biochem Biophys Res Commun</source> (<year>2007</year>) <volume>364</volume>:<fpage>509</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="doi">10.1016/j.bbrc.2007.10.077</pub-id><?supplied-pmid 17964546?><pub-id pub-id-type="pmid">17964546</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Georgantas</surname><given-names>RW</given-names><suffix>III</suffix></name><name><surname>Hildreth</surname><given-names>R</given-names></name><name><surname>Morisot</surname><given-names>S</given-names></name><name><surname>Alder</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>CG</given-names></name><name><surname>Heimfeld</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2007</year>) <volume>104</volume>:<fpage>2750</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0610983104</pub-id><?supplied-pmid 17293455?><pub-id pub-id-type="pmid">17293455</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffiths-Jones</surname><given-names>S</given-names></name></person-group>. <article-title>The microRNA registry</article-title>. <source>Nucleic Acids Res</source> (<year>2004</year>) <volume>32</volume>:<fpage>D109</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="doi">10.1093/nar/gkh023</pub-id><?supplied-pmid 14681370?><pub-id pub-id-type="pmid">14681370</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meijer</surname><given-names>HA</given-names></name><name><surname>Smith</surname><given-names>EM</given-names></name><name><surname>Bushell</surname><given-names>M</given-names></name></person-group>. <article-title>Regulation of miRNA strand selection: follow the leader?</article-title>
<source>Biochem Soc Trans</source> (<year>2014</year>) <volume>42</volume>:<fpage>1135</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="doi">10.1042/BST20140142</pub-id><?supplied-pmid 25110015?><pub-id pub-id-type="pmid">25110015</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohanian</surname><given-names>M</given-names></name><name><surname>Humphreys</surname><given-names>DT</given-names></name><name><surname>Anderson</surname><given-names>E</given-names></name><name><surname>Preiss</surname><given-names>T</given-names></name><name><surname>Fatkin</surname><given-names>D</given-names></name></person-group>. <article-title>A heterozygous variant in the human cardiac miR-133 gene, MIR133A2, alters miRNA duplex processing and strand abundance</article-title>. <source>BMC Genet</source> (<year>2013</year>) <volume>14</volume>:<fpage>18</fpage>.<pub-id pub-id-type="doi">10.1186/1471-2156-14-18</pub-id><?supplied-pmid 23497314?><pub-id pub-id-type="pmid">23497314</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neilsen</surname><given-names>CT</given-names></name><name><surname>Goodall</surname><given-names>GJ</given-names></name><name><surname>Bracken</surname><given-names>CP</given-names></name></person-group>
<article-title>IsomiRs &#8211; the overlooked repertoire in the dynamic microRNAome</article-title>. <source>Trends Genet</source> (<year>2012</year>) <volume>28</volume>:<fpage>544</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/j.tig.2012.07.005</pub-id><pub-id pub-id-type="pmid">22883467</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>HY</given-names></name><name><surname>Zhou</surname><given-names>K</given-names></name><name><surname>Smith</surname><given-names>AM</given-names></name><name><surname>Noland</surname><given-names>CL</given-names></name><name><surname>Doudna</surname><given-names>JA</given-names></name></person-group>. <article-title>Differential roles of human Dicer-binding proteins TRBP and PACT in small RNA processing</article-title>. <source>Nucleic Acids Res</source> (<year>2013</year>) <volume>41</volume>:<fpage>6568</fpage>&#8211;<lpage>76</lpage>.<pub-id pub-id-type="doi">10.1093/nar/gkt361</pub-id><?supplied-pmid 23661684?><pub-id pub-id-type="pmid">23661684</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bushati</surname><given-names>N</given-names></name><name><surname>Cohen</surname><given-names>SM</given-names></name></person-group>. <article-title>microRNA functions</article-title>. <source>Annu Rev Cell Dev Biol</source> (<year>2007</year>) <volume>23</volume>:<fpage>175</fpage>&#8211;<lpage>205</lpage>.<pub-id pub-id-type="doi">10.1146/annurev.cellbio.23.090506.123406</pub-id><?supplied-pmid 17506695?><pub-id pub-id-type="pmid">17506695</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filipowicz</surname><given-names>W</given-names></name><name><surname>Bhattacharyya</surname><given-names>SN</given-names></name><name><surname>Sonenberg</surname><given-names>N</given-names></name></person-group>. <article-title>Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?</article-title>
<source>Nat Rev Genet</source> (<year>2008</year>) <volume>9</volume>:<fpage>102</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="doi">10.1038/nrg2290</pub-id><?supplied-pmid 18197166?><pub-id pub-id-type="pmid">18197166</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Cui</surname><given-names>H</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>miR-155 and its star-form partner miR-155* cooperatively regulate type I interferon production by human plasmacytoid dendritic cells</article-title>. <source>Blood</source> (<year>2010</year>) <volume>116</volume>:<fpage>5885</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2010-04-280156</pub-id><?supplied-pmid 20852130?><pub-id pub-id-type="pmid">20852130</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarassishin</surname><given-names>L</given-names></name><name><surname>Loudig</surname><given-names>O</given-names></name><name><surname>Bauman</surname><given-names>A</given-names></name><name><surname>Shafit-Zagardo</surname><given-names>B</given-names></name><name><surname>Suh</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>SC</given-names></name></person-group>
<article-title>Interferon regulatory factor 3 inhibits astrocyte inflammatory gene expression through suppression of the proinflammatory miR-155 and miR-155</article-title>. <source>Glia</source> (<year>2011</year>) <volume>59</volume>:<fpage>1911</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="doi">10.1002/glia.21233</pub-id><pub-id pub-id-type="pmid">22170100</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#8217;Connell</surname><given-names>RM</given-names></name><name><surname>Taganov</surname><given-names>KD</given-names></name><name><surname>Boldin</surname><given-names>MP</given-names></name><name><surname>Cheng</surname><given-names>GH</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group>. <article-title>MicroRNA-155 is induced during the macrophage inflammatory response</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2007</year>) <volume>104</volume>:<fpage>1604</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0610731104</pub-id><?supplied-pmid 17242365?><pub-id pub-id-type="pmid">17242365</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurowska-Stolarska</surname><given-names>M</given-names></name><name><surname>Hasoo</surname><given-names>MK</given-names></name><name><surname>Welsh</surname><given-names>DJ</given-names></name><name><surname>Stewart</surname><given-names>L</given-names></name><name><surname>McIntyre</surname><given-names>D</given-names></name><name><surname>Morton</surname><given-names>BE</given-names></name><etal/></person-group>
<article-title>The role of microRNA-155/liver X receptor pathway in experimental and idiopathic pulmonary fibrosis</article-title>. <source>J Allergy Clin Immunol</source> (<year>2017</year>) <volume>139</volume>:<fpage>1946</fpage>&#8211;<lpage>56</lpage>.<pub-id pub-id-type="doi">10.1016/j.jaci.2016.09.021</pub-id><?supplied-pmid 27746237?><pub-id pub-id-type="pmid">27746237</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruning</surname><given-names>U</given-names></name><name><surname>Cerone</surname><given-names>L</given-names></name><name><surname>Neufeld</surname><given-names>Z</given-names></name><name><surname>Fitzpatrick</surname><given-names>SF</given-names></name><name><surname>Cheong</surname><given-names>A</given-names></name><name><surname>Scholz</surname><given-names>CC</given-names></name><etal/></person-group>
<article-title>MicroRNA-155 promotes resolution of hypoxia-inducible factor 1alpha activity during prolonged hypoxia</article-title>. <source>Mol Cell Biol</source> (<year>2011</year>) <volume>31</volume>:<fpage>4087</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="doi">10.1128/MCB.01276-10</pub-id><?supplied-pmid 21807897?><pub-id pub-id-type="pmid">21807897</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinn</surname><given-names>SR</given-names></name><name><surname>Mangan</surname><given-names>NE</given-names></name><name><surname>Caffrey</surname><given-names>BE</given-names></name><name><surname>Gantier</surname><given-names>MP</given-names></name><name><surname>Williams</surname><given-names>BR</given-names></name><name><surname>Hertzog</surname><given-names>PJ</given-names></name><etal/></person-group>
<article-title>The role of Ets2 transcription factor in the induction of microRNA-155 (miR-155) by lipopolysaccharide and its targeting by interleukin-10</article-title>. <source>J Biol Chem</source> (<year>2014</year>) <volume>289</volume>:<fpage>4316</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.M113.522730</pub-id><?supplied-pmid 24362029?><pub-id pub-id-type="pmid">24362029</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pottier</surname><given-names>N</given-names></name><name><surname>Maurin</surname><given-names>T</given-names></name><name><surname>Chevalier</surname><given-names>B</given-names></name><name><surname>Puissegur</surname><given-names>MP</given-names></name><name><surname>Lebrigand</surname><given-names>K</given-names></name><name><surname>Robbe-Sermesant</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Identification of keratinocyte growth factor as a target of microRNA-155 in lung fibroblasts: implication in epithelial-mesenchymal interactions</article-title>. <source>PLoS One</source> (<year>2009</year>) <volume>4</volume>:<fpage>e6718</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0006718</pub-id><pub-id pub-id-type="pmid">19701459</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>JJ</given-names></name><name><surname>Coppola</surname><given-names>D</given-names></name><name><surname>Dalton</surname><given-names>WS</given-names></name><etal/></person-group>
<article-title>MicroRNA-155 is regulated by the transforming growth factor beta/smad pathway and contributes to epithelial cell plasticity by targeting RhoA</article-title>. <source>Mol Cell Biol</source> (<year>2008</year>) <volume>28</volume>:<fpage>6773</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="doi">10.1128/MCB.00941-08</pub-id><?supplied-pmid 18794355?><pub-id pub-id-type="pmid">18794355</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valeri</surname><given-names>N</given-names></name><name><surname>Gasparini</surname><given-names>P</given-names></name><name><surname>Fabbri</surname><given-names>M</given-names></name><name><surname>Braconi</surname><given-names>C</given-names></name><name><surname>Veronese</surname><given-names>A</given-names></name><name><surname>Lovat</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Modulation of mismatch repair and genomic stability by miR-155</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2010</year>) <volume>107</volume>:<fpage>6982</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.1002472107</pub-id><?supplied-pmid 20351277?><pub-id pub-id-type="pmid">20351277</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Triantafyllou</surname><given-names>E</given-names></name><name><surname>Pop</surname><given-names>OT</given-names></name><name><surname>Possamai</surname><given-names>LA</given-names></name><name><surname>Wilhelm</surname><given-names>A</given-names></name><name><surname>Liaskou</surname><given-names>E</given-names></name><name><surname>Singanayagam</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure</article-title>. <source>Gut</source> (<year>2017</year>).<pub-id pub-id-type="doi">10.1136/gutjnl-2016-313615</pub-id><?supplied-pmid 28450389?><pub-id pub-id-type="pmid">28450389</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajasagi</surname><given-names>NK</given-names></name><name><surname>Bhela</surname><given-names>S</given-names></name><name><surname>Varanasi</surname><given-names>SK</given-names></name><name><surname>Rouse</surname><given-names>BT</given-names></name></person-group>. <article-title>Frontline science: aspirin-triggered resolvin D1 controls herpes simplex virus-induced corneal immunopathology</article-title>. <source>J Leukoc Biol</source> (<year>2017</year>) <volume>102</volume>:<fpage>1159</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="doi">10.1189/jlb.3HI1216-511RR</pub-id><?supplied-pmid 28584076?><pub-id pub-id-type="pmid">28584076</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Xiong</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Qian</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Glucocorticoids inhibit lipopolysaccharide-mediated inflammatory response by downregulating microRNA-155: a novel anti-inflammation mechanism</article-title>. <source>Free Radic Biol Med</source> (<year>2012</year>) <volume>52</volume>:<fpage>1307</fpage>&#8211;<lpage>17</lpage>.<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2012.01.031</pub-id><?supplied-pmid 22326887?><pub-id pub-id-type="pmid">22326887</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chinenov</surname><given-names>Y</given-names></name><name><surname>Coppo</surname><given-names>M</given-names></name><name><surname>Gupte</surname><given-names>R</given-names></name><name><surname>Sacta</surname><given-names>MA</given-names></name><name><surname>Rogatsky</surname><given-names>I</given-names></name></person-group>. <article-title>Glucocorticoid receptor coordinates transcription factor-dominated regulatory network in macrophages</article-title>. <source>BMC Genomics</source> (<year>2014</year>) <volume>15</volume>:<fpage>656</fpage>.<pub-id pub-id-type="doi">10.1186/1471-2164-15-656</pub-id><?supplied-pmid 25099603?><pub-id pub-id-type="pmid">25099603</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharyya</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>P</given-names></name><name><surname>Tsuchiya</surname><given-names>M</given-names></name><name><surname>Bhattacharyya</surname><given-names>A</given-names></name><name><surname>Biswas</surname><given-names>R</given-names></name></person-group>. <article-title>Regulation of miR-155 biogenesis in cystic fibrosis lung epithelial cells: antagonistic role of two mRNA-destabilizing proteins, KSRP and TTP</article-title>. <source>Biochem Biophys Res Commun</source> (<year>2013</year>) <volume>433</volume>:<fpage>484</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/j.bbrc.2013.03.025</pub-id><?supplied-pmid 23524258?><pub-id pub-id-type="pmid">23524258</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boldin</surname><given-names>MP</given-names></name><name><surname>Taganov</surname><given-names>KD</given-names></name><name><surname>Rao</surname><given-names>DS</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>JL</given-names></name><name><surname>Kalwani</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice</article-title>. <source>J Exp Med</source> (<year>2011</year>) <volume>208</volume>:<fpage>1189</fpage>&#8211;<lpage>201</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20101823</pub-id><?supplied-pmid 21555486?><pub-id pub-id-type="pmid">21555486</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mann</surname><given-names>M</given-names></name><name><surname>Mehta</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>JL</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Marinov</surname><given-names>GK</given-names></name><name><surname>Garcia-Flores</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>An NF-kappaB-microRNA regulatory network tunes macrophage inflammatory responses</article-title>. <source>Nat Commun</source> (<year>2017</year>) <volume>8</volume>:<fpage>851</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-00972-z</pub-id><pub-id pub-id-type="pmid">29021573</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elton</surname><given-names>TS</given-names></name><name><surname>Selemon</surname><given-names>H</given-names></name><name><surname>Elton</surname><given-names>SM</given-names></name><name><surname>Parinandi</surname><given-names>NL</given-names></name></person-group>. <article-title>Regulation of the MIR155 host gene in physiological and pathological processes</article-title>. <source>Gene</source> (<year>2013</year>) <volume>532</volume>:<fpage>1</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="doi">10.1016/j.gene.2012.12.009</pub-id><?supplied-pmid 23246696?><pub-id pub-id-type="pmid">23246696</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>PJ</given-names></name><name><surname>Allen</surname><given-names>JE</given-names></name><name><surname>Biswas</surname><given-names>SK</given-names></name><name><surname>Fisher</surname><given-names>EA</given-names></name><name><surname>Gilroy</surname><given-names>DW</given-names></name><name><surname>Goerdt</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Macrophage activation and polarization: nomenclature and experimental guidelines</article-title>. <source>Immunity</source> (<year>2014</year>) <volume>41</volume>:<fpage>14</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2014.06.008</pub-id><?supplied-pmid 25035950?><pub-id pub-id-type="pmid">25035950</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Misharin</surname><given-names>AV</given-names></name><name><surname>Cuda</surname><given-names>CM</given-names></name><name><surname>Saber</surname><given-names>R</given-names></name><name><surname>Turner</surname><given-names>JD</given-names></name><name><surname>Gierut</surname><given-names>AK</given-names></name><name><surname>Haines</surname><given-names>GK</given-names><suffix>III</suffix></name><etal/></person-group>
<article-title>Nonclassical Ly6C(-) monocytes drive the development of inflammatory arthritis in mice</article-title>. <source>Cell Rep</source> (<year>2014</year>) <volume>9</volume>:<fpage>591</fpage>&#8211;<lpage>604</lpage>.<pub-id pub-id-type="doi">10.1016/j.celrep.2014.09.032</pub-id><?supplied-pmid 25373902?><pub-id pub-id-type="pmid">25373902</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Self-Fordham</surname><given-names>JB</given-names></name><name><surname>Naqvi</surname><given-names>AR</given-names></name><name><surname>Uttamani</surname><given-names>JR</given-names></name><name><surname>Kulkarni</surname><given-names>V</given-names></name><name><surname>Nares</surname><given-names>S</given-names></name></person-group>
<article-title>MicroRNA: dynamic regulators of macrophage polarization and plasticity</article-title>. <source>Front Immunol</source> (<year>2017</year>) <volume>8</volume>:<fpage>1062</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.01062</pub-id><pub-id pub-id-type="pmid">28912781</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#8217;Connell</surname><given-names>RM</given-names></name><name><surname>Chaudhuri</surname><given-names>AA</given-names></name><name><surname>Rao</surname><given-names>DS</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group>. <article-title>Inositol phosphatase SHIP1 is a primary target of miR-155</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2009</year>) <volume>106</volume>:<fpage>7113</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0902636106</pub-id><?supplied-pmid 19359473?><pub-id pub-id-type="pmid">19359473</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>T</given-names></name><name><surname>Qian</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Src homology 2 domain-containing inositol-5-phosphatase 1 (SHIP1) negatively regulates TLR4-mediated LPS response primarily through a phosphatase activity- and PI-3K-independent mechanism</article-title>. <source>Blood</source> (<year>2005</year>) <volume>105</volume>:<fpage>4685</fpage>&#8211;<lpage>92</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2005-01-0191</pub-id><?supplied-pmid 15701712?><pub-id pub-id-type="pmid">15701712</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Inducible microRNA-155 feedback promotes type I IFN signaling in antiviral innate immunity by targeting suppressor of cytokine signaling 1</article-title>. <source>J Immunol</source> (<year>2010</year>) <volume>185</volume>:<fpage>6226</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1000491</pub-id><?supplied-pmid 20937844?><pub-id pub-id-type="pmid">20937844</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nazari-Jahantigh</surname><given-names>M</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Noels</surname><given-names>H</given-names></name><name><surname>Akhtar</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Koenen</surname><given-names>RR</given-names></name><etal/></person-group>
<article-title>MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages</article-title>. <source>J Clin Invest</source> (<year>2012</year>) <volume>122</volume>:<fpage>4190</fpage>&#8211;<lpage>202</lpage>.<pub-id pub-id-type="doi">10.1172/JCI61716</pub-id><?supplied-pmid 23041630?><pub-id pub-id-type="pmid">23041630</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurowska-Stolarska</surname><given-names>M</given-names></name><name><surname>Alivernini</surname><given-names>S</given-names></name><name><surname>Ballantine</surname><given-names>LE</given-names></name><name><surname>Asquith</surname><given-names>DL</given-names></name><name><surname>Millar</surname><given-names>NL</given-names></name><name><surname>Gilchrist</surname><given-names>DS</given-names></name><etal/></person-group>
<article-title>MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2011</year>) <volume>108</volume>:<fpage>11193</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.1019536108</pub-id><?supplied-pmid 21690378?><pub-id pub-id-type="pmid">21690378</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jing</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Hou</surname><given-names>X</given-names></name><name><surname>Yao</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name></person-group>. <article-title>CRISPR/CAS9-mediated genome editing of miRNA-155 inhibits proinflammatory cytokine production by RAW264.7 cells</article-title>. <source>Biomed Res Int</source> (<year>2015</year>) <volume>2015</volume>:<fpage>326042</fpage>.<pub-id pub-id-type="doi">10.1155/2015/326042</pub-id><?supplied-pmid 26697483?><pub-id pub-id-type="pmid">26697483</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Ding</surname><given-names>T</given-names></name><name><surname>Kuang</surname><given-names>DM</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name></person-group>. <article-title>MicroRNA-155 regulates inflammatory cytokine production in tumor-associated macrophages via targeting C/EBPbeta</article-title>. <source>Cell Mol Immunol</source> (<year>2009</year>) <volume>6</volume>:<fpage>343</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="doi">10.1038/cmi.2009.45</pub-id><?supplied-pmid 19887047?><pub-id pub-id-type="pmid">19887047</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H</given-names></name></person-group>. <article-title>The transcription factor MafB promotes anti-inflammatory M2 polarization and cholesterol efflux in macrophages</article-title>. <source>Sci Rep</source> (<year>2017</year>) <volume>7</volume>:<fpage>7591</fpage>.<pub-id pub-id-type="doi">10.1038/s41598-017-07381-8</pub-id><?supplied-pmid 28790455?><pub-id pub-id-type="pmid">28790455</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Nunez</surname><given-names>RT</given-names></name><name><surname>Louafi</surname><given-names>F</given-names></name><name><surname>Sanchez-Elsner</surname><given-names>T</given-names></name></person-group>. <article-title>The interleukin 13 (IL-13) pathway in human macrophages is modulated by microRNA-155 via direct targeting of interleukin 13 receptor alpha1 (IL13Ralpha1)</article-title>. <source>J Biol Chem</source> (<year>2011</year>) <volume>286</volume>:<fpage>1786</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.M110.169367</pub-id><?supplied-pmid 21097505?><pub-id pub-id-type="pmid">21097505</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wahl</surname><given-names>SM</given-names></name><name><surname>Allen</surname><given-names>JB</given-names></name><name><surname>Costa</surname><given-names>GL</given-names></name><name><surname>Wong</surname><given-names>HL</given-names></name><name><surname>Dasch</surname><given-names>JR</given-names></name></person-group>. <article-title>Reversal of acute and chronic synovial inflammation by anti-transforming growth factor beta</article-title>. <source>J Exp Med</source> (<year>1993</year>) <volume>177</volume>:<fpage>225</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="doi">10.1084/jem.177.1.225</pub-id><?supplied-pmid 8418203?><pub-id pub-id-type="pmid">8418203</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louafi</surname><given-names>F</given-names></name><name><surname>Martinez-Nunez</surname><given-names>RT</given-names></name><name><surname>Sanchez-Elsner</surname><given-names>T</given-names></name></person-group>. <article-title>MicroRNA-155 targets SMAD2 and modulates the response of macrophages to transforming growth factor-{beta}</article-title>. <source>J Biol Chem</source> (<year>2010</year>) <volume>285</volume>:<fpage>41328</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.M110.146852</pub-id><?supplied-pmid 21036908?><pub-id pub-id-type="pmid">21036908</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bluml</surname><given-names>S</given-names></name><name><surname>Bonelli</surname><given-names>M</given-names></name><name><surname>Niederreiter</surname><given-names>B</given-names></name><name><surname>Puchner</surname><given-names>A</given-names></name><name><surname>Mayr</surname><given-names>G</given-names></name><name><surname>Hayer</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Essential role of microRNA-155 in the pathogenesis of autoimmune arthritis in mice</article-title>. <source>Arthritis Rheum</source> (<year>2011</year>) <volume>63</volume>:<fpage>1281</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1002/art.30281</pub-id><?supplied-pmid 21321928?><pub-id pub-id-type="pmid">21321928</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elmesmari</surname><given-names>A</given-names></name><name><surname>Fraser</surname><given-names>AR</given-names></name><name><surname>Wood</surname><given-names>C</given-names></name><name><surname>Gilchrist</surname><given-names>D</given-names></name><name><surname>Vaughan</surname><given-names>D</given-names></name><name><surname>Stewart</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>MicroRNA-155 regulates monocyte chemokine and chemokine receptor expression in rheumatoid arthritis</article-title>. <source>Rheumatology (Oxford)</source> (<year>2016</year>) <volume>55</volume>:<fpage>2056</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="doi">10.1093/rheumatology/kew272</pub-id><?supplied-pmid 27411480?><pub-id pub-id-type="pmid">27411480</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanczyk</surname><given-names>J</given-names></name><name><surname>Pedrioli</surname><given-names>DM</given-names></name><name><surname>Brentano</surname><given-names>F</given-names></name><name><surname>Sanchez-Pernaute</surname><given-names>O</given-names></name><name><surname>Kolling</surname><given-names>C</given-names></name><name><surname>Gay</surname><given-names>RE</given-names></name><etal/></person-group>
<article-title>Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis</article-title>. <source>Arthritis Rheum</source> (<year>2008</year>) <volume>58</volume>:<fpage>1001</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1002/art.23386</pub-id><?supplied-pmid 18383392?><pub-id pub-id-type="pmid">18383392</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>FJ</given-names></name><name><surname>An</surname><given-names>LN</given-names></name><name><surname>Wang</surname><given-names>GK</given-names></name><name><surname>Zhu</surname><given-names>JQ</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>YY</given-names></name><etal/></person-group>
<article-title>Elevated microRNA-155 promotes foam cell formation by targeting HBP1 in atherogenesis</article-title>. <source>Cardiovasc Res</source> (<year>2014</year>) <volume>103</volume>:<fpage>100</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="doi">10.1093/cvr/cvu070</pub-id><?supplied-pmid 24675724?><pub-id pub-id-type="pmid">24675724</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herenius</surname><given-names>MM</given-names></name><name><surname>Thurlings</surname><given-names>RM</given-names></name><name><surname>Wijbrandts</surname><given-names>CA</given-names></name><name><surname>Bennink</surname><given-names>RJ</given-names></name><name><surname>Dohmen</surname><given-names>SE</given-names></name><name><surname>Voermans</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Monocyte migration to the synovium in rheumatoid arthritis patients treated with adalimumab</article-title>. <source>Ann Rheum Dis</source> (<year>2011</year>) <volume>70</volume>:<fpage>1160</fpage>&#8211;<lpage>2</lpage>.<pub-id pub-id-type="doi">10.1136/ard.2010.141549</pub-id><?supplied-pmid 21345816?><pub-id pub-id-type="pmid">21345816</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asquith</surname><given-names>DL</given-names></name><name><surname>Bryce</surname><given-names>SA</given-names></name><name><surname>Nibbs</surname><given-names>RJ</given-names></name></person-group>. <article-title>Targeting cell migration in rheumatoid arthritis</article-title>. <source>Curr Opin Rheumatol</source> (<year>2015</year>) <volume>27</volume>:<fpage>204</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="doi">10.1097/BOR.0000000000000150</pub-id><?supplied-pmid 25603038?><pub-id pub-id-type="pmid">25603038</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>BR</given-names></name><name><surname>Yoo</surname><given-names>SJ</given-names></name><name><surname>Choi</surname><given-names>Y</given-names></name><name><surname>Chung</surname><given-names>YH</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Yoo</surname><given-names>IS</given-names></name><etal/></person-group>
<article-title>Functional phenotype of synovial monocytes modulating inflammatory T-cell responses in rheumatoid arthritis (RA)</article-title>. <source>PLoS One</source> (<year>2014</year>) <volume>9</volume>:<fpage>e109775</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0109775</pub-id><pub-id pub-id-type="pmid">25329467</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walter</surname><given-names>GJ</given-names></name><name><surname>Evans</surname><given-names>HG</given-names></name><name><surname>Menon</surname><given-names>B</given-names></name><name><surname>Gullick</surname><given-names>NJ</given-names></name><name><surname>Kirkham</surname><given-names>BW</given-names></name><name><surname>Cope</surname><given-names>AP</given-names></name><etal/></person-group>
<article-title>Interaction with activated monocytes enhances cytokine expression and suppressive activity of human CD4+CD45ro+CD25+CD127(low) regulatory T cells</article-title>. <source>Arthritis Rheum</source> (<year>2013</year>) <volume>65</volume>:<fpage>627</fpage>&#8211;<lpage>38</lpage>.<pub-id pub-id-type="doi">10.1002/art.37832</pub-id><?supplied-pmid 23280063?><pub-id pub-id-type="pmid">23280063</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>HG</given-names></name><name><surname>Gullick</surname><given-names>NJ</given-names></name><name><surname>Kelly</surname><given-names>S</given-names></name><name><surname>Pitzalis</surname><given-names>C</given-names></name><name><surname>Lord</surname><given-names>GM</given-names></name><name><surname>Kirkham</surname><given-names>BW</given-names></name><etal/></person-group>
<article-title>In vivo activated monocytes from the site of inflammation in humans specifically promote Th17 responses</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2009</year>) <volume>106</volume>:<fpage>6232</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0808144106</pub-id><?supplied-pmid 19325128?><pub-id pub-id-type="pmid">19325128</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Firestein</surname><given-names>GS</given-names></name><name><surname>Zvaifler</surname><given-names>NJ</given-names></name></person-group>
<article-title>Peripheral blood and synovial fluid monocyte activation in inflammatory arthritis. i. a cytofluorographic study of monocyte differentiation antigens and class ii antigens and their regulation by &#947;gm-interferon</article-title>. <source>Arthritis Rheum</source> (<year>1987</year>) <volume>30</volume>:<fpage>857</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1002/art.1780300803</pub-id><pub-id pub-id-type="pmid">3115273</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Highton</surname><given-names>J</given-names></name><name><surname>Carlisle</surname><given-names>B</given-names></name><name><surname>Palmer</surname><given-names>DG</given-names></name></person-group>
<article-title>Changes in the phenotype of monocytes/macrophages and expression of cytokine mRNA in peripheral blood and synovial fluid of patients with rheumatoid arthritis</article-title>. <source>Clin Exp Immunol</source> (<year>2008</year>) <volume>102</volume>:<fpage>541</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1111/j.1365-2249.1995.tb03850.x</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Rycke</surname><given-names>L</given-names></name><name><surname>Baeten</surname><given-names>D</given-names></name><name><surname>Foell</surname><given-names>D</given-names></name><name><surname>Kruithof</surname><given-names>E</given-names></name><name><surname>Veys</surname><given-names>EM</given-names></name><name><surname>Roth</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Differential expression and response to anti-TNFalpha treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis</article-title>. <source>J Pathol</source> (<year>2005</year>) <volume>206</volume>:<fpage>17</fpage>&#8211;<lpage>27</lpage>.<pub-id pub-id-type="doi">10.1002/path.1758</pub-id><?supplied-pmid 15809977?><pub-id pub-id-type="pmid">15809977</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>CQ</given-names></name><name><surname>Field</surname><given-names>M</given-names></name><name><surname>Feldmann</surname><given-names>M</given-names></name><name><surname>Maini</surname><given-names>RN</given-names></name></person-group>
<article-title>Localization of tumor-necrosis-factor-alpha in synovial tissues and at the cartilage pannus junction in patients with rheumatoid-arthritis</article-title>. <source>Arthritis Rheum</source> (<year>1991</year>) <volume>34</volume>:<fpage>1125</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1002/art.1780340908</pub-id><pub-id pub-id-type="pmid">1930331</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danks</surname><given-names>L</given-names></name><name><surname>Sabokbar</surname><given-names>A</given-names></name><name><surname>Gundle</surname><given-names>R</given-names></name><name><surname>Athanasou</surname><given-names>NA</given-names></name></person-group>. <article-title>Synovial macrophage-osteoclast differentiation in inflammatory arthritis</article-title>. <source>Ann Rheum Dis</source> (<year>2002</year>) <volume>61</volume>:<fpage>916</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="doi">10.1136/ard.61.10.916</pub-id><?supplied-pmid 12228163?><pub-id pub-id-type="pmid">12228163</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adamopoulos</surname><given-names>IE</given-names></name><name><surname>Sabokbar</surname><given-names>A</given-names></name><name><surname>Wordsworth</surname><given-names>BP</given-names></name><name><surname>Carr</surname><given-names>A</given-names></name><name><surname>Ferguson</surname><given-names>DJ</given-names></name><name><surname>Athanasou</surname><given-names>NA</given-names></name></person-group>. <article-title>Synovial fluid macrophages are capable of osteoclast formation and resorption</article-title>. <source>J Pathol</source> (<year>2006</year>) <volume>208</volume>:<fpage>35</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="doi">10.1002/path.1891</pub-id><?supplied-pmid 16278818?><pub-id pub-id-type="pmid">16278818</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Syed</surname><given-names>S</given-names></name><name><surname>Amin</surname><given-names>M</given-names></name><name><surname>Rabquer</surname><given-names>B</given-names></name></person-group>
<article-title>miR155 expression is increased by inflammation and modulates the expression of CD11a in monocytes</article-title>. <source>FASEB J</source> (<year>2015</year>) <volume>29</volume>(<issue>Suppl 1</issue>):<fpage>634.6</fpage>.</mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perlman</surname><given-names>H</given-names></name><name><surname>Pagliari</surname><given-names>LJ</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Koch</surname><given-names>AE</given-names></name><name><surname>Haines</surname><given-names>GK</given-names></name><name><surname>Pope</surname><given-names>RM</given-names></name></person-group>
<article-title>Rheumatoid arthritis synovial macrophages express the Fas-associated death domain-like interleukin-1?-converting enzyme-inhibitory protein and are refractory to Fas-mediated apoptosis</article-title>. <source>Arthritis Rheum</source> (<year>2001</year>) <volume>44</volume>:<fpage>21</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="doi">10.1002/1529-0131(200101)44:1&lt;21::AID-ANR4&gt;3.0.CO;2-8</pub-id><pub-id pub-id-type="pmid">11212162</pub-id></mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Shi</surname><given-names>B</given-names></name><name><surname>Eksarko</surname><given-names>P</given-names></name><name><surname>Temkin</surname><given-names>V</given-names></name><name><surname>Pope</surname><given-names>RM</given-names></name></person-group>. <article-title>Regulation of Mcl-1 expression in rheumatoid arthritis synovial macrophages</article-title>. <source>Arthritis Rheum</source> (<year>2006</year>) <volume>54</volume>:<fpage>3174</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1002/art.22132</pub-id><?supplied-pmid 17009247?><pub-id pub-id-type="pmid">17009247</pub-id></mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meusch</surname><given-names>U</given-names></name><name><surname>Rossol</surname><given-names>M</given-names></name><name><surname>Baerwald</surname><given-names>C</given-names></name><name><surname>Hauschildt</surname><given-names>S</given-names></name><name><surname>Wagner</surname><given-names>U</given-names></name></person-group>. <article-title>Outside-to-inside signaling through transmembrane tumor necrosis factor reverses pathologic interleukin-1beta production and deficient apoptosis of rheumatoid arthritis monocytes</article-title>. <source>Arthritis Rheum</source> (<year>2009</year>) <volume>60</volume>:<fpage>2612</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="doi">10.1002/art.24778</pub-id><?supplied-pmid 19714631?><pub-id pub-id-type="pmid">19714631</pub-id></mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>S</given-names></name><name><surname>Macaubas</surname><given-names>C</given-names></name><name><surname>Deshpande</surname><given-names>C</given-names></name><name><surname>Alexander</surname><given-names>HC</given-names></name><name><surname>Chang</surname><given-names>SY</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Monocytes are resistant to apoptosis in systemic juvenile idiopathic arthritis</article-title>. <source>Clin Immunol</source> (<year>2010</year>) <volume>136</volume>:<fpage>257</fpage>&#8211;<lpage>68</lpage>.<pub-id pub-id-type="doi">10.1016/j.clim.2010.04.003</pub-id><?supplied-pmid 20462799?><pub-id pub-id-type="pmid">20462799</pub-id></mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajasekhar</surname><given-names>M</given-names></name><name><surname>Olsson</surname><given-names>AM</given-names></name><name><surname>Steel</surname><given-names>KJ</given-names></name><name><surname>Georgouli</surname><given-names>M</given-names></name><name><surname>Ranasinghe</surname><given-names>U</given-names></name><name><surname>Brender Read</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>MicroRNA-155 contributes to enhanced resistance to apoptosis in monocytes from patients with rheumatoid arthritis</article-title>. <source>J Autoimmun</source> (<year>2017</year>) <volume>79</volume>:<fpage>53</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="doi">10.1016/j.jaut.2017.01.002</pub-id><?supplied-pmid 28118944?><pub-id pub-id-type="pmid">28118944</pub-id></mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Xi</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Macrophage-derived mir-155-containing exosomes suppress fibroblast proliferation and promote fibroblast inflammation during cardiac injury</article-title>. <source>Mol Ther</source> (<year>2017</year>) <volume>25</volume>:<fpage>192</fpage>&#8211;<lpage>204</lpage>.<pub-id pub-id-type="doi">10.1016/j.ymthe.2016.09.001</pub-id><?supplied-pmid 28129114?><pub-id pub-id-type="pmid">28129114</pub-id></mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinman</surname><given-names>RM</given-names></name><name><surname>Banchereau</surname><given-names>J</given-names></name></person-group>. <article-title>Taking dendritic cells into medicine</article-title>. <source>Nature</source> (<year>2007</year>) <volume>449</volume>:<fpage>419</fpage>&#8211;<lpage>26</lpage>.<pub-id pub-id-type="doi">10.1038/nature06175</pub-id><?supplied-pmid 17898760?><pub-id pub-id-type="pmid">17898760</pub-id></mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banchereau</surname><given-names>J</given-names></name><name><surname>Steinman</surname><given-names>RM</given-names></name></person-group>. <article-title>Dendritic cells and the control of immunity</article-title>. <source>Nature</source> (<year>1998</year>) <volume>392</volume>:<fpage>245</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="doi">10.1038/32588</pub-id><?supplied-pmid 9521319?><pub-id pub-id-type="pmid">9521319</pub-id></mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>HB</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name></person-group>. <article-title>The development and function of dendritic cell populations and their regulation by miRNAs</article-title>. <source>Protein Cell</source> (<year>2017</year>) <volume>8</volume>:<fpage>501</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="doi">10.1007/s13238-017-0398-2</pub-id><?supplied-pmid 28364278?><pub-id pub-id-type="pmid">28364278</pub-id></mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reis e Sousa</surname><given-names>C</given-names></name></person-group>
<article-title>Dendritic cells in a mature age</article-title>. <source>Nat Rev Immunol</source> (<year>2006</year>) <volume>6</volume>:<fpage>476</fpage>&#8211;<lpage>83</lpage>.<pub-id pub-id-type="doi">10.1038/nri1845</pub-id><pub-id pub-id-type="pmid">16691244</pub-id></mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawai</surname><given-names>T</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group>. <article-title>TLR signaling</article-title>. <source>Cell Death Differ</source> (<year>2006</year>) <volume>13</volume>:<fpage>816</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="doi">10.1038/sj.cdd.4401850</pub-id><?supplied-pmid 16410796?><pub-id pub-id-type="pmid">16410796</pub-id></mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunand-Sauthier</surname><given-names>I</given-names></name><name><surname>Santiago-Raber</surname><given-names>ML</given-names></name><name><surname>Capponi</surname><given-names>L</given-names></name><name><surname>Vejnar</surname><given-names>CE</given-names></name><name><surname>Schaad</surname><given-names>O</given-names></name><name><surname>Irla</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Silencing of c-Fos expression by microRNA-155 is critical for dendritic cell maturation and function</article-title>. <source>Blood</source> (<year>2011</year>) <volume>117</volume>:<fpage>4490</fpage>&#8211;<lpage>500</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2010-09-308064</pub-id><?supplied-pmid 21385848?><pub-id pub-id-type="pmid">21385848</pub-id></mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceppi</surname><given-names>M</given-names></name><name><surname>Pereira</surname><given-names>PM</given-names></name><name><surname>Dunand-Sauthier</surname><given-names>I</given-names></name><name><surname>Barras</surname><given-names>E</given-names></name><name><surname>Reith</surname><given-names>W</given-names></name><name><surname>Santos</surname><given-names>MA</given-names></name><etal/></person-group>
<article-title>MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2009</year>) <volume>106</volume>:<fpage>2735</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0811073106</pub-id><?supplied-pmid 19193853?><pub-id pub-id-type="pmid">19193853</pub-id></mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Nunez</surname><given-names>RT</given-names></name><name><surname>Louafi</surname><given-names>F</given-names></name><name><surname>Friedmann</surname><given-names>PS</given-names></name><name><surname>Sanchez-Elsner</surname><given-names>T</given-names></name></person-group>. <article-title>MicroRNA-155 modulates the pathogen binding ability of dendritic cells (DCs) by down-regulation of DC-specific intercellular adhesion molecule-3 grabbing non-integrin (DC-SIGN)</article-title>. <source>J Biol Chem</source> (<year>2009</year>) <volume>284</volume>:<fpage>16334</fpage>&#8211;<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.M109.011601</pub-id><?supplied-pmid 19386588?><pub-id pub-id-type="pmid">19386588</pub-id></mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Tesar</surname><given-names>BM</given-names></name><name><surname>Walker</surname><given-names>WE</given-names></name><name><surname>Goldstein</surname><given-names>DR</given-names></name></person-group>. <article-title>Dual signaling of MyD88 and TRIF is critical for maximal TLR4-induced dendritic cell maturation</article-title>. <source>J Immunol</source> (<year>2008</year>) <volume>181</volume>:<fpage>1849</fpage>&#8211;<lpage>58</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.181.3.1849</pub-id><?supplied-pmid 18641322?><pub-id pub-id-type="pmid">18641322</pub-id></mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dudziak</surname><given-names>D</given-names></name><name><surname>Kamphorst</surname><given-names>AO</given-names></name><name><surname>Heidkamp</surname><given-names>GF</given-names></name><name><surname>Buchholz</surname><given-names>VR</given-names></name><name><surname>Trumpfheller</surname><given-names>C</given-names></name><name><surname>Yamazaki</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Differential antigen processing by dendritic cell subsets in vivo</article-title>. <source>Science</source> (<year>2007</year>) <volume>315</volume>:<fpage>107</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="doi">10.1126/science.1136080</pub-id><?supplied-pmid 17204652?><pub-id pub-id-type="pmid">17204652</pub-id></mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lind</surname><given-names>EF</given-names></name><name><surname>Millar</surname><given-names>DG</given-names></name><name><surname>Dissanayake</surname><given-names>D</given-names></name><name><surname>Savage</surname><given-names>JC</given-names></name><name><surname>Grimshaw</surname><given-names>NK</given-names></name><name><surname>Kerr</surname><given-names>WG</given-names></name><etal/></person-group>
<article-title>miR-155 upregulation in dendritic cells is sufficient to break tolerance in vivo by negatively regulating SHIP1</article-title>. <source>J Immunol</source> (<year>2015</year>) <volume>195</volume>:<fpage>4632</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1302941</pub-id><?supplied-pmid 26447227?><pub-id pub-id-type="pmid">26447227</pub-id></mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Roensch</surname><given-names>K</given-names></name><name><surname>Cao</surname><given-names>Q</given-names></name><name><surname>Nakayama</surname><given-names>KI</given-names></name><etal/></person-group>
<article-title>miR-221 and miR-155 regulate human dendritic cell development, apoptosis, and IL-12 production through targeting of p27kip1, KPC1, and SOCS-1</article-title>. <source>Blood</source> (<year>2011</year>) <volume>117</volume>:<fpage>4293</fpage>&#8211;<lpage>303</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2010-12-322503</pub-id><?supplied-pmid 21355095?><pub-id pub-id-type="pmid">21355095</pub-id></mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>A</given-names></name><name><surname>Vigorito</surname><given-names>E</given-names></name><name><surname>Clare</surname><given-names>S</given-names></name><name><surname>Warren</surname><given-names>MV</given-names></name><name><surname>Couttet</surname><given-names>P</given-names></name><name><surname>Soond</surname><given-names>DR</given-names></name><etal/></person-group>
<article-title>Requirement of bic/microRNA-155 for normal immune function</article-title>. <source>Science</source> (<year>2007</year>) <volume>316</volume>:<fpage>608</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="doi">10.1126/science.1139253</pub-id><?supplied-pmid 17463290?><pub-id pub-id-type="pmid">17463290</pub-id></mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jongbloed</surname><given-names>SL</given-names></name><name><surname>Lebre</surname><given-names>MC</given-names></name><name><surname>Fraser</surname><given-names>AR</given-names></name><name><surname>Gracie</surname><given-names>JA</given-names></name><name><surname>Sturrock</surname><given-names>RD</given-names></name><name><surname>Tak</surname><given-names>PP</given-names></name><etal/></person-group>
<article-title>Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis</article-title>. <source>Arthritis Res Ther</source> (<year>2006</year>) <volume>8</volume>:<fpage>R15</fpage>.<pub-id pub-id-type="doi">10.1186/ar1864</pub-id><?supplied-pmid 16507115?><pub-id pub-id-type="pmid">16507115</pub-id></mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurowska-Stolarska</surname><given-names>M</given-names></name><name><surname>Alivernini</surname><given-names>S</given-names></name><name><surname>Melchor</surname><given-names>EG</given-names></name><name><surname>Elmesmari</surname><given-names>A</given-names></name><name><surname>Tolusso</surname><given-names>B</given-names></name><name><surname>Tange</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>MicroRNA-34a dependent regulation of AXL controls the activation of dendritic cells in inflammatory arthritis</article-title>. <source>Nat Commun</source> (<year>2017</year>) <volume>8</volume>:<fpage>15877</fpage>.<pub-id pub-id-type="doi">10.1038/ncomms15877</pub-id><?supplied-pmid 28639625?><pub-id pub-id-type="pmid">28639625</pub-id></mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moret</surname><given-names>FM</given-names></name><name><surname>Bijlsma</surname><given-names>JWJ</given-names></name><name><surname>Lafeber</surname><given-names>FPJG</given-names></name><name><surname>van Roon</surname><given-names>JAG</given-names></name></person-group>. <article-title>The efficacy of abatacept in reducing synovial T cell activation by CD1c myeloid dendritic cells is overruled by the stimulatory effects of T cell-activating cytokines</article-title>. <source>Arthritis Rheumatol</source> (<year>2015</year>) <volume>67</volume>:<fpage>637</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1002/art.38982</pub-id><?supplied-pmid 25469671?><pub-id pub-id-type="pmid">25469671</pub-id></mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moret</surname><given-names>FM</given-names></name><name><surname>Hack</surname><given-names>CE</given-names></name><name><surname>van der Wurff-Jacobs</surname><given-names>KM</given-names></name><name><surname>de Jager</surname><given-names>W</given-names></name><name><surname>Radstake</surname><given-names>TR</given-names></name><name><surname>Lafeber</surname><given-names>FP</given-names></name><etal/></person-group>
<article-title>Intra-articular CD1c-expressing myeloid dendritic cells from rheumatoid arthritis patients express a unique set of T cell-attracting chemokines and spontaneously induce Th1, Th17 and Th2 cell activity</article-title>. <source>Arthritis Res Ther</source> (<year>2013</year>) <volume>15</volume>:<fpage>R155</fpage>.<pub-id pub-id-type="doi">10.1186/ar4338</pub-id><?supplied-pmid 24286358?><pub-id pub-id-type="pmid">24286358</pub-id></mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thai</surname><given-names>TH</given-names></name><name><surname>Calado</surname><given-names>DP</given-names></name><name><surname>Casola</surname><given-names>S</given-names></name><name><surname>Ansel</surname><given-names>KM</given-names></name><name><surname>Xiao</surname><given-names>C</given-names></name><name><surname>Xue</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Regulation of the germinal center response by microRNA-155</article-title>. <source>Science</source> (<year>2007</year>) <volume>316</volume>:<fpage>604</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1126/science.1141229</pub-id><?supplied-pmid 17463289?><pub-id pub-id-type="pmid">17463289</pub-id></mixed-citation></ref><ref id="B104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musilova</surname><given-names>K</given-names></name><name><surname>Mraz</surname><given-names>M</given-names></name></person-group>. <article-title>MicroRNAs in B-cell lymphomas: how a complex biology gets more complex</article-title>. <source>Leukemia</source> (<year>2015</year>) <volume>29</volume>:<fpage>1004</fpage>&#8211;<lpage>17</lpage>.<pub-id pub-id-type="doi">10.1038/leu.2014.351</pub-id><?supplied-pmid 25541152?><pub-id pub-id-type="pmid">25541152</pub-id></mixed-citation></ref><ref id="B105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costinean</surname><given-names>S</given-names></name><name><surname>Sandhu</surname><given-names>SK</given-names></name><name><surname>Pedersen</surname><given-names>IM</given-names></name><name><surname>Tili</surname><given-names>E</given-names></name><name><surname>Trotta</surname><given-names>R</given-names></name><name><surname>Perrotti</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice</article-title>. <source>Blood</source> (<year>2009</year>) <volume>114</volume>:<fpage>1374</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2009-05-220814</pub-id><pub-id pub-id-type="pmid">19520806</pub-id></mixed-citation></ref><ref id="B106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costinean</surname><given-names>S</given-names></name><name><surname>Zanesi</surname><given-names>N</given-names></name><name><surname>Pekarsky</surname><given-names>Y</given-names></name><name><surname>Tili</surname><given-names>E</given-names></name><name><surname>Volinia</surname><given-names>S</given-names></name><name><surname>Heerema</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2006</year>) <volume>103</volume>:<fpage>7024</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0602266103</pub-id><?supplied-pmid 16641092?><pub-id pub-id-type="pmid">16641092</pub-id></mixed-citation></ref><ref id="B107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandhu</surname><given-names>SK</given-names></name><name><surname>Volinia</surname><given-names>S</given-names></name><name><surname>Costinean</surname><given-names>S</given-names></name><name><surname>Galasso</surname><given-names>M</given-names></name><name><surname>Neinast</surname><given-names>R</given-names></name><name><surname>Santhanam</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the E mu-miR-155 transgenic mouse model</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2012</year>) <volume>109</volume>:<fpage>20047</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.1213764109</pub-id><pub-id pub-id-type="pmid">23169640</pub-id></mixed-citation></ref><ref id="B108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>D</given-names></name><name><surname>Aguiar</surname><given-names>RC</given-names></name></person-group>
<article-title>MicroRNA-155 controls RB phosphorylation in normal and malignant B lymphocytes via the noncanonical TGF-beta1/SMAD5 signaling module</article-title>. <source>Blood</source> (<year>2014</year>) <volume>123</volume>:<fpage>86</fpage>&#8211;<lpage>93</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2013-07-515254</pub-id><pub-id pub-id-type="pmid">24136167</pub-id></mixed-citation></ref><ref id="B109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babar</surname><given-names>IA</given-names></name><name><surname>Cheng</surname><given-names>CJ</given-names></name><name><surname>Booth</surname><given-names>CJ</given-names></name><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Weidhaas</surname><given-names>JB</given-names></name><name><surname>Saltzman</surname><given-names>WM</given-names></name><etal/></person-group>
<article-title>Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2012</year>) <volume>109</volume>:<fpage>E1695</fpage>&#8211;<lpage>704</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.1201516109</pub-id><?supplied-pmid 22685206?><pub-id pub-id-type="pmid">22685206</pub-id></mixed-citation></ref><ref id="B110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>U</given-names></name><name><surname>Dalla-Favera</surname><given-names>R</given-names></name></person-group>. <article-title>Germinal centres: role in B-cell physiology and malignancy</article-title>. <source>Nat Rev Immunol</source> (<year>2008</year>) <volume>8</volume>:<fpage>22</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="doi">10.1038/nri2217</pub-id><?supplied-pmid 18097447?><pub-id pub-id-type="pmid">18097447</pub-id></mixed-citation></ref><ref id="B111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Mraz</surname><given-names>M</given-names></name><name><surname>Fecteau</surname><given-names>JF</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia</article-title>. <source>Blood</source> (<year>2014</year>) <volume>124</volume>:<fpage>546</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2014-03-559690</pub-id><?supplied-pmid 24914134?><pub-id pub-id-type="pmid">24914134</pub-id></mixed-citation></ref><ref id="B112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vigorito</surname><given-names>E</given-names></name><name><surname>Perks</surname><given-names>KL</given-names></name><name><surname>Abreu-Goodger</surname><given-names>C</given-names></name><name><surname>Bunting</surname><given-names>S</given-names></name><name><surname>Xiang</surname><given-names>Z</given-names></name><name><surname>Kohlhaas</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells</article-title>. <source>Immunity</source> (<year>2007</year>) <volume>27</volume>:<fpage>847</fpage>&#8211;<lpage>59</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2007.10.009</pub-id><?supplied-pmid 18055230?><pub-id pub-id-type="pmid">18055230</pub-id></mixed-citation></ref><ref id="B113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thai</surname><given-names>TH</given-names></name><name><surname>Patterson</surname><given-names>HC</given-names></name><name><surname>Pham</surname><given-names>DH</given-names></name><name><surname>Kis-Toth</surname><given-names>K</given-names></name><name><surname>Kaminski</surname><given-names>DA</given-names></name><name><surname>Tsokos</surname><given-names>GC</given-names></name></person-group>. <article-title>Deletion of microRNA-155 reduces autoantibody responses and alleviates lupus-like disease in the Fas(lpr) mouse</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2013</year>) <volume>110</volume>:<fpage>20194</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.1317632110</pub-id><?supplied-pmid 24282294?><pub-id pub-id-type="pmid">24282294</pub-id></mixed-citation></ref><ref id="B114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>D</given-names></name><name><surname>Nakagawa</surname><given-names>R</given-names></name><name><surname>Lazzaro</surname><given-names>S</given-names></name><name><surname>Staudacher</surname><given-names>P</given-names></name><name><surname>Abreu-Goodger</surname><given-names>C</given-names></name><name><surname>Henley</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>The miR-155-PU.1 axis acts on Pax5 to enable efficient terminal B cell differentiation</article-title>. <source>J Exp Med</source> (<year>2014</year>) <volume>211</volume>:<fpage>2183</fpage>&#8211;<lpage>98</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20140338</pub-id><?supplied-pmid 25288398?><pub-id pub-id-type="pmid">25288398</pub-id></mixed-citation></ref><ref id="B115"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Fan</surname><given-names>H</given-names></name><name><surname>Ren</surname><given-names>D</given-names></name><name><surname>Dong</surname><given-names>G</given-names></name><name><surname>Hu</surname><given-names>E</given-names></name><name><surname>Ji</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>TLR9-induced miR-155 and Ets-1 decrease expression of CD1d on B cells in SLE</article-title>. <source>Eur J Immunol</source> (<year>2015</year>) <volume>45</volume>:<fpage>1934</fpage>&#8211;<lpage>45</lpage>.<pub-id pub-id-type="doi">10.1002/eji.201445286</pub-id><?supplied-pmid 25929465?><pub-id pub-id-type="pmid">25929465</pub-id></mixed-citation></ref><ref id="B116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Stadt</surname><given-names>LA</given-names></name><name><surname>de Koning</surname><given-names>MH</given-names></name><name><surname>van de Stadt</surname><given-names>RJ</given-names></name><name><surname>Wolbink</surname><given-names>G</given-names></name><name><surname>Dijkmans</surname><given-names>BA</given-names></name><name><surname>Hamann</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis</article-title>. <source>Arthritis Rheum</source> (<year>2011</year>) <volume>63</volume>:<fpage>3226</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="doi">10.1002/art.30537</pub-id><?supplied-pmid 21792832?><pub-id pub-id-type="pmid">21792832</pub-id></mixed-citation></ref><ref id="B117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferraccioli</surname><given-names>G</given-names></name><name><surname>Tolusso</surname><given-names>B</given-names></name><name><surname>Bobbio-Pallavicini</surname><given-names>F</given-names></name><name><surname>Gremese</surname><given-names>E</given-names></name><name><surname>Ravagnani</surname><given-names>V</given-names></name><name><surname>Benucci</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis</article-title>. <source>PLoS One</source> (<year>2012</year>) <volume>7</volume>:<fpage>e40362</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0040362</pub-id><pub-id pub-id-type="pmid">22859946</pub-id></mixed-citation></ref><ref id="B118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fekete</surname><given-names>A</given-names></name><name><surname>Soos</surname><given-names>L</given-names></name><name><surname>Szekanecz</surname><given-names>Z</given-names></name><name><surname>Szabo</surname><given-names>Z</given-names></name><name><surname>Szodoray</surname><given-names>P</given-names></name><name><surname>Barath</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Disturbances in B- and T-cell homeostasis in rheumatoid arthritis: suggested relationships with antigen-driven immune responses</article-title>. <source>J Autoimmun</source> (<year>2007</year>) <volume>29</volume>:<fpage>154</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1016/j.jaut.2007.07.002</pub-id><?supplied-pmid 17826949?><pub-id pub-id-type="pmid">17826949</pub-id></mixed-citation></ref><ref id="B119"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Souto-Carneiro</surname><given-names>MM</given-names></name><name><surname>Mahadevan</surname><given-names>V</given-names></name><name><surname>Takada</surname><given-names>K</given-names></name><name><surname>Fritsch-Stork</surname><given-names>R</given-names></name><name><surname>Nanki</surname><given-names>T</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor</article-title>. <source>Arthritis Res Ther</source> (<year>2009</year>) <volume>11</volume>:<fpage>R84</fpage>.<pub-id pub-id-type="doi">10.1186/ar2718</pub-id><?supplied-pmid 19500335?><pub-id pub-id-type="pmid">19500335</pub-id></mixed-citation></ref><ref id="B120"><label>120</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fedele</surname><given-names>AL</given-names></name><name><surname>Tolusso</surname><given-names>B</given-names></name><name><surname>Gremese</surname><given-names>E</given-names></name><name><surname>Bosello</surname><given-names>SL</given-names></name><name><surname>Carbonella</surname><given-names>A</given-names></name><name><surname>Canestri</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Memory B cell subsets and plasmablasts are lower in early than in long-standing rheumatoid arthritis</article-title>. <source>BMC Immunol</source> (<year>2014</year>) <volume>15</volume>:<fpage>28</fpage><pub-id pub-id-type="doi">10.1186/s12865-014-0028-1</pub-id><pub-id pub-id-type="pmid">25187226</pub-id></mixed-citation></ref><ref id="B121"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alivernini</surname><given-names>S</given-names></name><name><surname>Kurowska-Stolarska</surname><given-names>M</given-names></name><name><surname>Tolusso</surname><given-names>B</given-names></name><name><surname>Benvenuto</surname><given-names>R</given-names></name><name><surname>Elmesmari</surname><given-names>A</given-names></name><name><surname>Canestri</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>MicroRNA-155 influences B-cell function through PU.1 in rheumatoid arthritis</article-title>. <source>Nat Commun</source> (<year>2016</year>) <volume>7</volume>:<fpage>12970</fpage>.<pub-id pub-id-type="doi">10.1038/ncomms12970</pub-id><?supplied-pmid 27671860?><pub-id pub-id-type="pmid">27671860</pub-id></mixed-citation></ref><ref id="B122"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahmood</surname><given-names>Z</given-names></name><name><surname>Muhammad</surname><given-names>K</given-names></name><name><surname>Schmalzing</surname><given-names>M</given-names></name><name><surname>Roll</surname><given-names>P</given-names></name><name><surname>Dorner</surname><given-names>T</given-names></name><name><surname>Tony</surname><given-names>HP</given-names></name></person-group>. <article-title>CD27-IgD- memory B cells are modulated by in vivo interleukin-6 receptor (IL-6R) blockade in rheumatoid arthritis</article-title>. <source>Arthritis Res Ther</source> (<year>2015</year>) <volume>17</volume>:<fpage>61</fpage>.<pub-id pub-id-type="doi">10.1186/s13075-015-0580-y</pub-id><?supplied-pmid 25888920?><pub-id pub-id-type="pmid">25888920</pub-id></mixed-citation></ref><ref id="B123"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Bayona</surname><given-names>B</given-names></name><name><surname>Ramos-Amaya</surname><given-names>A</given-names></name><name><surname>Perez-Venegas</surname><given-names>JJ</given-names></name><name><surname>Rodriguez</surname><given-names>C</given-names></name><name><surname>Brieva</surname><given-names>JA</given-names></name></person-group>. <article-title>Decreased frequency and activated phenotype of blood CD27 IgD IgM B lymphocytes is a permanent abnormality in systemic lupus erythematosus patients</article-title>. <source>Arthritis Res Ther</source> (<year>2010</year>) <volume>12</volume>:<fpage>R108</fpage>.<pub-id pub-id-type="doi">10.1186/ar3042</pub-id><?supplied-pmid 20525218?><pub-id pub-id-type="pmid">20525218</pub-id></mixed-citation></ref><ref id="B124"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tangye</surname><given-names>SG</given-names></name><name><surname>Tarlinton</surname><given-names>DM</given-names></name></person-group>. <article-title>Memory B cells: effectors of long-lived immune responses</article-title>. <source>Eur J Immunol</source> (<year>2009</year>) <volume>39</volume>:<fpage>2065</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="doi">10.1002/eji.200939531</pub-id><?supplied-pmid 19637202?><pub-id pub-id-type="pmid">19637202</pub-id></mixed-citation></ref><ref id="B125"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orr</surname><given-names>C</given-names></name><name><surname>Najm</surname><given-names>A</given-names></name><name><surname>Biniecka</surname><given-names>M</given-names></name><name><surname>McGarry</surname><given-names>T</given-names></name><name><surname>Ng</surname><given-names>CT</given-names></name><name><surname>Young</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Synovial immunophenotype and anti-citrullinated peptide antibodies in rheumatoid arthritis patients: relationship to treatment response and radiologic prognosis</article-title>. <source>Arthritis Rheumatol</source> (<year>2017</year>) <volume>69</volume>:<fpage>2114</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="doi">10.1002/art.40218</pub-id><?supplied-pmid 28732135?><pub-id pub-id-type="pmid">28732135</pub-id></mixed-citation></ref><ref id="B126"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitzalis</surname><given-names>C</given-names></name><name><surname>Kelly</surname><given-names>S</given-names></name><name><surname>Humby</surname><given-names>F</given-names></name></person-group>. <article-title>New learnings on the pathophysiology of RA from synovial biopsies</article-title>. <source>Curr Opin Rheumatol</source> (<year>2013</year>) <volume>25</volume>:<fpage>334</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1097/BOR.0b013e32835fd8eb</pub-id><?supplied-pmid 23492740?><pub-id pub-id-type="pmid">23492740</pub-id></mixed-citation></ref><ref id="B127"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Yamane</surname><given-names>H</given-names></name><name><surname>Paul</surname><given-names>WE</given-names></name></person-group>. <article-title>Differentiation of effector CD4 T cell populations (*)</article-title>. <source>Annu Rev Immunol</source> (<year>2010</year>) <volume>28</volume>:<fpage>445</fpage>&#8211;<lpage>89</lpage>.<pub-id pub-id-type="doi">10.1146/annurev-immunol-030409-101212</pub-id><?supplied-pmid 20192806?><pub-id pub-id-type="pmid">20192806</pub-id></mixed-citation></ref><ref id="B128"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reiner</surname><given-names>SL</given-names></name></person-group>. <article-title>Development in motion: helper T cells at work</article-title>. <source>Cell</source> (<year>2007</year>) <volume>129</volume>:<fpage>33</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/j.cell.2007.03.019</pub-id><?supplied-pmid 17418783?><pub-id pub-id-type="pmid">17418783</pub-id></mixed-citation></ref><ref id="B129"><label>129</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cobb</surname><given-names>BS</given-names></name><name><surname>Nesterova</surname><given-names>TB</given-names></name><name><surname>Thompson</surname><given-names>E</given-names></name><name><surname>Hertweck</surname><given-names>A</given-names></name><name><surname>O&#8217;Connor</surname><given-names>E</given-names></name><name><surname>Godwin</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>T cell lineage choice and differentiation in the absence of the RNase III enzyme Dicer</article-title>. <source>J Exp Med</source> (<year>2005</year>) <volume>201</volume>:<fpage>1367</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20050572</pub-id><?supplied-pmid 15867090?><pub-id pub-id-type="pmid">15867090</pub-id></mixed-citation></ref><ref id="B130"><label>130</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muljo</surname><given-names>SA</given-names></name><name><surname>Ansel</surname><given-names>KM</given-names></name><name><surname>Kanellopoulou</surname><given-names>C</given-names></name><name><surname>Livingston</surname><given-names>DM</given-names></name><name><surname>Rao</surname><given-names>A</given-names></name><name><surname>Rajewsky</surname><given-names>K</given-names></name></person-group>. <article-title>Aberrant T cell differentiation in the absence of Dicer</article-title>. <source>J Exp Med</source> (<year>2005</year>) <volume>202</volume>:<fpage>261</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20050678</pub-id><?supplied-pmid 16009718?><pub-id pub-id-type="pmid">16009718</pub-id></mixed-citation></ref><ref id="B131"><label>131</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>A</given-names></name><name><surname>Schambach</surname><given-names>F</given-names></name><name><surname>DeJong</surname><given-names>CS</given-names></name><name><surname>Hammond</surname><given-names>SM</given-names></name><name><surname>Reiner</surname><given-names>SL</given-names></name></person-group>. <article-title>Micro-RNA-155 inhibits IFN-gamma signaling in CD4+ T cells</article-title>. <source>Eur J Immunol</source> (<year>2010</year>) <volume>40</volume>:<fpage>225</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1002/eji.200939381</pub-id><?supplied-pmid 19877012?><pub-id pub-id-type="pmid">19877012</pub-id></mixed-citation></ref><ref id="B132"><label>132</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eis</surname><given-names>PS</given-names></name><name><surname>Tam</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Chadburn</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Gomez</surname><given-names>MF</given-names></name><etal/></person-group>
<article-title>Accumulation of miR-155 and BIC RNA in human B cell lymphomas</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2005</year>) <volume>102</volume>:<fpage>3627</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0500613102</pub-id><?supplied-pmid 15738415?><pub-id pub-id-type="pmid">15738415</pub-id></mixed-citation></ref><ref id="B133"><label>133</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haasch</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>YW</given-names></name><name><surname>Reilly</surname><given-names>RM</given-names></name><name><surname>Chiou</surname><given-names>XG</given-names></name><name><surname>Koterski</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>ML</given-names></name><etal/></person-group>
<article-title>T cell activation induces a noncoding RNA transcript sensitive to inhibition by immunosuppressant drugs and encoded by the proto-oncogene, BIC</article-title>. <source>Cell Immunol</source> (<year>2002</year>) <volume>217</volume>:<fpage>78</fpage>&#8211;<lpage>86</lpage>.<pub-id pub-id-type="doi">10.1016/S0008-8749(02)00506-3</pub-id><?supplied-pmid 12426003?><pub-id pub-id-type="pmid">12426003</pub-id></mixed-citation></ref><ref id="B134"><label>134</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Berg</surname><given-names>A</given-names></name><name><surname>Kroesen</surname><given-names>BJ</given-names></name><name><surname>Kooistra</surname><given-names>K</given-names></name><name><surname>de Jong</surname><given-names>D</given-names></name><name><surname>Briggs</surname><given-names>J</given-names></name><name><surname>Blokzijl</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>High expression of B-cell receptor inducible gene BIC in all subtypes of Hodgkin lymphoma</article-title>. <source>Genes Chromosomes Cancer</source> (<year>2003</year>) <volume>37</volume>:<fpage>20</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1002/gcc.10186</pub-id><?supplied-pmid 12661002?><pub-id pub-id-type="pmid">12661002</pub-id></mixed-citation></ref><ref id="B135"><label>135</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malmhall</surname><given-names>C</given-names></name><name><surname>Alawieh</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Sjostrand</surname><given-names>M</given-names></name><name><surname>Bossios</surname><given-names>A</given-names></name><name><surname>Eldh</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>MicroRNA-155 is essential for T(H)2-mediated allergen-induced eosinophilic inflammation in the lung</article-title>. <source>J Allergy Clin Immunol</source> (<year>2014</year>) <volume>133</volume>:<fpage>1429</fpage>&#8211;<lpage>38, 1438.e1&#8211;7</lpage>.<pub-id pub-id-type="doi">10.1016/j.jaci.2013.11.008</pub-id><?supplied-pmid 24373357?><pub-id pub-id-type="pmid">24373357</pub-id></mixed-citation></ref><ref id="B136"><label>136</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okoye</surname><given-names>IS</given-names></name><name><surname>Czieso</surname><given-names>S</given-names></name><name><surname>Ktistaki</surname><given-names>E</given-names></name><name><surname>Roderick</surname><given-names>K</given-names></name><name><surname>Coomes</surname><given-names>SM</given-names></name><name><surname>Pelly</surname><given-names>VS</given-names></name><etal/></person-group>
<article-title>Transcriptomics identified a critical role for Th2 cell-intrinsic miR-155 in mediating allergy and antihelminth immunity</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2014</year>) <volume>111</volume>:<fpage>E3081</fpage>&#8211;<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.1406322111</pub-id><?supplied-pmid 25024218?><pub-id pub-id-type="pmid">25024218</pub-id></mixed-citation></ref><ref id="B137"><label>137</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escobar</surname><given-names>TM</given-names></name><name><surname>Kanellopoulou</surname><given-names>C</given-names></name><name><surname>Kugler</surname><given-names>DG</given-names></name><name><surname>Kilaru</surname><given-names>G</given-names></name><name><surname>Nguyen</surname><given-names>CK</given-names></name><name><surname>Nagarajan</surname><given-names>V</given-names></name><etal/></person-group>
<article-title>miR-155 activates cytokine gene expression in Th17 cells by regulating the DNA-binding protein Jarid2 to relieve polycomb-mediated repression</article-title>. <source>Immunity</source> (<year>2014</year>) <volume>40</volume>:<fpage>865</fpage>&#8211;<lpage>79</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2014.03.014</pub-id><?supplied-pmid 24856900?><pub-id pub-id-type="pmid">24856900</pub-id></mixed-citation></ref><ref id="B138"><label>138</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>R</given-names></name><name><surname>Ma</surname><given-names>YL</given-names></name><name><surname>Liang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>HH</given-names></name><name><surname>Ma</surname><given-names>ZJ</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>MicroRNA-155 modulates Treg and Th17 cells differentiation and Th17 cell function by targeting SOCS1</article-title>. <source>PLoS One</source> (<year>2012</year>) <volume>7</volume>:<fpage>e46082</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0046082</pub-id><?supplied-pmid 23091595?><pub-id pub-id-type="pmid">23091595</pub-id></mixed-citation></ref><ref id="B139"><label>139</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#8217;Connell</surname><given-names>RM</given-names></name><name><surname>Kahn</surname><given-names>D</given-names></name><name><surname>Gibson</surname><given-names>WS</given-names></name><name><surname>Round</surname><given-names>JL</given-names></name><name><surname>Scholz</surname><given-names>RL</given-names></name><name><surname>Chaudhuri</surname><given-names>AA</given-names></name><etal/></person-group>
<article-title>MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development</article-title>. <source>Immunity</source> (<year>2010</year>) <volume>33</volume>:<fpage>607</fpage>&#8211;<lpage>19</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2010.09.009</pub-id><?supplied-pmid 20888269?><pub-id pub-id-type="pmid">20888269</pub-id></mixed-citation></ref><ref id="B140"><label>140</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>R</given-names></name><name><surname>Huffaker</surname><given-names>TB</given-names></name><name><surname>Kagele</surname><given-names>DA</given-names></name><name><surname>Runtsch</surname><given-names>MC</given-names></name><name><surname>Bake</surname><given-names>E</given-names></name><name><surname>Chaudhuri</surname><given-names>AA</given-names></name><etal/></person-group>
<article-title>MicroRNA-155 confers encephalogenic potential to Th17 cells by promoting effector gene expression</article-title>. <source>J Immunol</source> (<year>2013</year>) <volume>190</volume>:<fpage>5972</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1300351</pub-id><?supplied-pmid 23686497?><pub-id pub-id-type="pmid">23686497</pub-id></mixed-citation></ref><ref id="B141"><label>141</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murugaiyan</surname><given-names>G</given-names></name><name><surname>Beynon</surname><given-names>V</given-names></name><name><surname>Mittal</surname><given-names>A</given-names></name><name><surname>Joller</surname><given-names>N</given-names></name><name><surname>Weiner</surname><given-names>HL</given-names></name></person-group>. <article-title>Silencing microRNA-155 ameliorates experimental autoimmune encephalomyelitis</article-title>. <source>J Immunol</source> (<year>2011</year>) <volume>187</volume>:<fpage>2213</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1003952</pub-id><?supplied-pmid 21788439?><pub-id pub-id-type="pmid">21788439</pub-id></mixed-citation></ref><ref id="B142"><label>142</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>R</given-names></name><name><surname>Kagele</surname><given-names>DA</given-names></name><name><surname>Huffaker</surname><given-names>TB</given-names></name><name><surname>Runtsch</surname><given-names>MC</given-names></name><name><surname>Alexander</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>miR-155 promotes T follicular helper cell accumulation during chronic, low-grade inflammation</article-title>. <source>Immunity</source> (<year>2014</year>) <volume>41</volume>:<fpage>605</fpage>&#8211;<lpage>19</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2014.09.015</pub-id><?supplied-pmid 25367574?><pub-id pub-id-type="pmid">25367574</pub-id></mixed-citation></ref><ref id="B143"><label>143</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohlhaas</surname><given-names>S</given-names></name><name><surname>Garden</surname><given-names>OA</given-names></name><name><surname>Scudamore</surname><given-names>C</given-names></name><name><surname>Turner</surname><given-names>M</given-names></name><name><surname>Okkenhaug</surname><given-names>K</given-names></name><name><surname>Vigorito</surname><given-names>E</given-names></name></person-group>. <article-title>Cutting edge: the Foxp3 target miR-155 contributes to the development of regulatory T cells</article-title>. <source>J Immunol</source> (<year>2009</year>) <volume>182</volume>:<fpage>2578</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.0803162</pub-id><?supplied-pmid 19234151?><pub-id pub-id-type="pmid">19234151</pub-id></mixed-citation></ref><ref id="B144"><label>144</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>LF</given-names></name><name><surname>Thai</surname><given-names>TH</given-names></name><name><surname>Calado</surname><given-names>DP</given-names></name><name><surname>Chaudhry</surname><given-names>A</given-names></name><name><surname>Kubo</surname><given-names>M</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein</article-title>. <source>Immunity</source> (<year>2009</year>) <volume>30</volume>:<fpage>80</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2008.11.010</pub-id><?supplied-pmid 19144316?><pub-id pub-id-type="pmid">19144316</pub-id></mixed-citation></ref><ref id="B145"><label>145</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asirvatham</surname><given-names>AJ</given-names></name><name><surname>Gregorie</surname><given-names>CJ</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Magner</surname><given-names>WJ</given-names></name><name><surname>Tomasi</surname><given-names>TB</given-names></name></person-group>. <article-title>MicroRNA targets in immune genes and the Dicer/Argonaute and ARE machinery components</article-title>. <source>Mol Immunol</source> (<year>2008</year>) <volume>45</volume>:<fpage>1995</fpage>&#8211;<lpage>2006</lpage>.<pub-id pub-id-type="doi">10.1016/j.molimm.2007.10.035</pub-id><?supplied-pmid 18061676?><pub-id pub-id-type="pmid">18061676</pub-id></mixed-citation></ref><ref id="B146"><label>146</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonkoly</surname><given-names>E</given-names></name><name><surname>Janson</surname><given-names>P</given-names></name><name><surname>Majuri</surname><given-names>ML</given-names></name><name><surname>Savinko</surname><given-names>T</given-names></name><name><surname>Fyhrquist</surname><given-names>N</given-names></name><name><surname>Eidsmo</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>MiR-155 is overexpressed in patients with atopic dermatitis and modulates T-cell proliferative responses by targeting cytotoxic T lymphocyte-associated antigen 4</article-title>. <source>J Allergy ClinImmunol</source> (<year>2010</year>) <volume>126</volume>:<fpage>581</fpage>&#8211;<lpage>9.e1&#8211;20</lpage>.<pub-id pub-id-type="doi">10.1016/j.jaci.2010.05.045</pub-id><?supplied-pmid 20673989?><pub-id pub-id-type="pmid">20673989</pub-id></mixed-citation></ref><ref id="B147"><label>147</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Bevan</surname><given-names>MJ</given-names></name></person-group>. <article-title>Dicer controls CD8+ T-cell activation, migration, and survival</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2010</year>) <volume>107</volume>:<fpage>21629</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.1016299107</pub-id><?supplied-pmid 21098294?><pub-id pub-id-type="pmid">21098294</pub-id></mixed-citation></ref><ref id="B148"><label>148</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gracias</surname><given-names>DT</given-names></name><name><surname>Stelekati</surname><given-names>E</given-names></name><name><surname>Hope</surname><given-names>JL</given-names></name><name><surname>Boesteanu</surname><given-names>AC</given-names></name><name><surname>Doering</surname><given-names>TA</given-names></name><name><surname>Norton</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>The microRNA miR-155 controls CD8(+) T cell responses by regulating interferon signaling</article-title>. <source>Nat Immunol</source> (<year>2013</year>) <volume>14</volume>:<fpage>593</fpage>&#8211;<lpage>602</lpage>.<pub-id pub-id-type="doi">10.1038/ni.2576</pub-id><?supplied-pmid 23603793?><pub-id pub-id-type="pmid">23603793</pub-id></mixed-citation></ref><ref id="B149"><label>149</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smigielska-Czepiel</surname><given-names>K</given-names></name><name><surname>van den Berg</surname><given-names>A</given-names></name><name><surname>Jellema</surname><given-names>P</given-names></name><name><surname>van der Lei</surname><given-names>RJ</given-names></name><name><surname>Bijzet</surname><given-names>J</given-names></name><name><surname>Kluiver</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Comprehensive analysis of miRNA expression in T-cell subsets of rheumatoid arthritis patients reveals defined signatures of naive and memory Tregs</article-title>. <source>Genes Immun</source> (<year>2014</year>) <volume>15</volume>:<fpage>115</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="doi">10.1038/gene.2013.69</pub-id><?supplied-pmid 24401767?><pub-id pub-id-type="pmid">24401767</pub-id></mixed-citation></ref><ref id="B150"><label>150</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dejaco</surname><given-names>C</given-names></name><name><surname>Duftner</surname><given-names>C</given-names></name><name><surname>Klauser</surname><given-names>A</given-names></name><name><surname>Schirmer</surname><given-names>M</given-names></name></person-group>. <article-title>Altered T-cell subtypes in spondyloarthritis, rheumatoid arthritis and polymyalgia rheumatica</article-title>. <source>Rheumatol Int</source> (<year>2010</year>) <volume>30</volume>:<fpage>297</fpage>&#8211;<lpage>303</lpage>.<pub-id pub-id-type="doi">10.1007/s00296-009-0949-9</pub-id><?supplied-pmid 19444449?><pub-id pub-id-type="pmid">19444449</pub-id></mixed-citation></ref><ref id="B151"><label>151</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mottonen</surname><given-names>M</given-names></name><name><surname>Heikkinen</surname><given-names>J</given-names></name><name><surname>Mustonen</surname><given-names>L</given-names></name><name><surname>Isomaki</surname><given-names>P</given-names></name><name><surname>Luukkainen</surname><given-names>R</given-names></name><name><surname>Lassila</surname><given-names>O</given-names></name></person-group>. <article-title>CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis</article-title>. <source>Clin Exp Immunol</source> (<year>2005</year>) <volume>140</volume>:<fpage>360</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1111/j.1365-2249.2005.02754.x</pub-id><?supplied-pmid 15807863?><pub-id pub-id-type="pmid">15807863</pub-id></mixed-citation></ref><ref id="B152"><label>152</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raghavan</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>D</given-names></name><name><surname>Widhe</surname><given-names>M</given-names></name><name><surname>Roth</surname><given-names>K</given-names></name><name><surname>Herrath</surname><given-names>J</given-names></name><name><surname>Engstrom</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>FOXP3 expression in blood, synovial fluid and synovial tissue during inflammatory arthritis and intra-articular corticosteroid treatment</article-title>. <source>Ann Rheum Dis</source> (<year>2009</year>) <volume>68</volume>:<fpage>1908</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="doi">10.1136/ard.2008.100768</pub-id><?supplied-pmid 19066178?><pub-id pub-id-type="pmid">19066178</pub-id></mixed-citation></ref><ref id="B153"><label>153</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Amelsfort</surname><given-names>JM</given-names></name><name><surname>Jacobs</surname><given-names>KM</given-names></name><name><surname>Bijlsma</surname><given-names>JW</given-names></name><name><surname>Lafeber</surname><given-names>FP</given-names></name><name><surname>Taams</surname><given-names>LS</given-names></name></person-group>. <article-title>CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid</article-title>. <source>Arthritis Rheum</source> (<year>2004</year>) <volume>50</volume>:<fpage>2775</fpage>&#8211;<lpage>85</lpage>.<pub-id pub-id-type="doi">10.1002/art.20499</pub-id><?supplied-pmid 15457445?><pub-id pub-id-type="pmid">15457445</pub-id></mixed-citation></ref><ref id="B154"><label>154</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valencia</surname><given-names>X</given-names></name><name><surname>Stephens</surname><given-names>G</given-names></name><name><surname>Goldbach-Mansky</surname><given-names>R</given-names></name><name><surname>Wilson</surname><given-names>M</given-names></name><name><surname>Shevach</surname><given-names>EM</given-names></name><name><surname>Lipsky</surname><given-names>PE</given-names></name></person-group>. <article-title>TNF downmodulates the function of human CD4+CD25hi T-regulatory cells</article-title>. <source>Blood</source> (<year>2006</year>) <volume>108</volume>:<fpage>253</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2005-11-4567</pub-id><?supplied-pmid 16537805?><pub-id pub-id-type="pmid">16537805</pub-id></mixed-citation></ref><ref id="B155"><label>155</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wehrens</surname><given-names>EJ</given-names></name><name><surname>Prakken</surname><given-names>BJ</given-names></name><name><surname>van Wijk</surname><given-names>F</given-names></name></person-group>
<article-title>T cells out of control &#8211; impaired immune regulation in the inflamed joint</article-title>. <source>Nat Rev Rheumatol</source> (<year>2013</year>) <volume>9</volume>:<fpage>34</fpage>&#8211;<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1038/nrrheum.2012.149</pub-id><pub-id pub-id-type="pmid">23390638</pub-id></mixed-citation></ref><ref id="B156"><label>156</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Haupt</surname><given-names>S</given-names></name><name><surname>Kreuzer</surname><given-names>JT</given-names></name><name><surname>Hammitzsch</surname><given-names>A</given-names></name><name><surname>Proft</surname><given-names>F</given-names></name><name><surname>Neumann</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Decreased expression of miR-146a and miR-155 contributes to an abnormal Treg phenotype in patients with rheumatoid arthritis</article-title>. <source>Ann Rheum Dis</source> (<year>2015</year>) <volume>74</volume>:<fpage>1265</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="doi">10.1136/annrheumdis-2013-204377</pub-id><?supplied-pmid 24562503?><pub-id pub-id-type="pmid">24562503</pub-id></mixed-citation></ref><ref id="B157"><label>157</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Rodriguez</surname><given-names>S</given-names></name><name><surname>Arias-Santiago</surname><given-names>S</given-names></name><name><surname>Blasco-Morente</surname><given-names>G</given-names></name><name><surname>Orgaz-Molina</surname><given-names>J</given-names></name><name><surname>Rosal-Vela</surname><given-names>A</given-names></name><name><surname>Navarro</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Increased expression of microRNA-155 in peripheral blood mononuclear cells from psoriasis patients is related to disease activity</article-title>. <source>J Eur Acad Dermatol Venereol</source> (<year>2017</year>) <volume>31</volume>:<fpage>312</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="doi">10.1111/jdv.13861</pub-id><?supplied-pmid 27535005?><pub-id pub-id-type="pmid">27535005</pub-id></mixed-citation></ref><ref id="B158"><label>158</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jopling</surname><given-names>CL</given-names></name><name><surname>Yi</surname><given-names>M</given-names></name><name><surname>Lancaster</surname><given-names>AM</given-names></name><name><surname>Lemon</surname><given-names>SM</given-names></name><name><surname>Sarnow</surname><given-names>P</given-names></name></person-group>. <article-title>Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA</article-title>. <source>Science</source> (<year>2005</year>) <volume>309</volume>:<fpage>1577</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1126/science.1113329</pub-id><?supplied-pmid 16141076?><pub-id pub-id-type="pmid">16141076</pub-id></mixed-citation></ref><ref id="B159"><label>159</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Misso</surname><given-names>G</given-names></name><name><surname>Di Martino</surname><given-names>MT</given-names></name><name><surname>De Rosa</surname><given-names>G</given-names></name><name><surname>Farooqi</surname><given-names>AA</given-names></name><name><surname>Lombardi</surname><given-names>A</given-names></name><name><surname>Campani</surname><given-names>V</given-names></name><etal/></person-group>
<article-title>Mir-34: a new weapon against cancer?</article-title>
<source>Mol Ther Nucleic Acids</source> (<year>2014</year>) <volume>3</volume>:<fpage>e194</fpage>.<pub-id pub-id-type="doi">10.1038/mtna.2014.47</pub-id><?supplied-pmid 25247240?><pub-id pub-id-type="pmid">25247240</pub-id></mixed-citation></ref><ref id="B160"><label>160</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Millar</surname><given-names>NL</given-names></name><name><surname>Gilchrist</surname><given-names>DS</given-names></name><name><surname>Akbar</surname><given-names>M</given-names></name><name><surname>Reilly</surname><given-names>JH</given-names></name><name><surname>Kerr</surname><given-names>SC</given-names></name><name><surname>Campbell</surname><given-names>AL</given-names></name><etal/></person-group>
<article-title>MicroRNA29a regulates IL-33-mediated tissue remodelling in tendon disease</article-title>. <source>Nat Commun</source> (<year>2015</year>) <volume>6</volume>:<fpage>6774</fpage>.<pub-id pub-id-type="doi">10.1038/ncomms7774</pub-id><?supplied-pmid 25857925?><pub-id pub-id-type="pmid">25857925</pub-id></mixed-citation></ref><ref id="B161"><label>161</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morton</surname><given-names>B</given-names></name><name><surname>Neben</surname><given-names>S</given-names></name><name><surname>Gibson</surname><given-names>N</given-names></name><name><surname>McSharry</surname><given-names>C</given-names></name><name><surname>McInnes</surname><given-names>IB</given-names></name><name><surname>Kurowska-Stolarska</surname><given-names>M</given-names></name></person-group>
<article-title>Neutralisation of miR-155 ameliorates collagen-induced arthritis</article-title>. <source>Ann Rheum Dis</source> (<year>2015</year>) <volume>74</volume>:<fpage>84</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1136/annrheumdis-2015-207259.194</pub-id></mixed-citation></ref><ref id="B162"><label>162</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>AM</given-names></name><name><surname>Gilchrist</surname><given-names>DS</given-names></name><name><surname>Nijjar</surname><given-names>J</given-names></name><name><surname>Araldi</surname><given-names>E</given-names></name><name><surname>Ramirez</surname><given-names>CM</given-names></name><name><surname>Lavery</surname><given-names>CA</given-names></name><etal/></person-group>
<article-title>MiR-155 has a protective role in the development of non-alcoholic hepatosteatosis in mice</article-title>. <source>PLoS One</source> (<year>2013</year>) <volume>8</volume>:<fpage>e72324</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0072324</pub-id><?supplied-pmid 23991091?><pub-id pub-id-type="pmid">23991091</pub-id></mixed-citation></ref><ref id="B163"><label>163</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>CJ</given-names></name><name><surname>Bahal</surname><given-names>R</given-names></name><name><surname>Babar</surname><given-names>IA</given-names></name><name><surname>Pincus</surname><given-names>Z</given-names></name><name><surname>Barrera</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>MicroRNA silencing for cancer therapy targeted to the tumour microenvironment</article-title>. <source>Nature</source> (<year>2015</year>) <volume>518</volume>:<fpage>107</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="doi">10.1038/nature13905</pub-id><?supplied-pmid 25409146?><pub-id pub-id-type="pmid">25409146</pub-id></mixed-citation></ref><ref id="B164"><label>164</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>CT</given-names></name><name><surname>Biniecka</surname><given-names>M</given-names></name><name><surname>Kennedy</surname><given-names>A</given-names></name><name><surname>McCormick</surname><given-names>J</given-names></name><name><surname>Fitzgerald</surname><given-names>O</given-names></name><name><surname>Bresnihan</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Synovial tissue hypoxia and inflammation in vivo</article-title>. <source>Ann Rheum Dis</source> (<year>2010</year>) <volume>69</volume>:<fpage>1389</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="doi">10.1136/ard.2009.119776</pub-id><?supplied-pmid 20439288?><pub-id pub-id-type="pmid">20439288</pub-id></mixed-citation></ref><ref id="B165"><label>165</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cross</surname><given-names>J</given-names></name><name><surname>Stenton</surname><given-names>GR</given-names></name><name><surname>Harwig</surname><given-names>C</given-names></name><name><surname>Szabo</surname><given-names>C</given-names></name><name><surname>Genovese</surname><given-names>T</given-names></name><name><surname>Di Paola</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>AQX-1125, small molecule SHIP1 activator inhibits bleomycin-induced pulmonary fibrosis</article-title>. <source>Br J Pharmacol</source> (<year>2017</year>) <volume>174</volume>:<fpage>3045</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="doi">10.1111/bph.13934</pub-id><?supplied-pmid 28658529?><pub-id pub-id-type="pmid">28658529</pub-id></mixed-citation></ref></ref-list></back></article>